UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 
(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2020

2021

or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _____________
Commission file numbernumber: 001-11460

 

NTN Buzztime,


Brooklyn ImmunoTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

DELAWAREDelaware 31-1103425

(State of

incorporation)

 

(I.R.S. Employer

Identification No.)


1800 ASTON AVENUE, SUITE 100, CARLSBAD,

CALIFORNIA

140 58th Street, Suite 2100, Brooklyn, New York 11220
 92008
(Address of principal executive offices) (Zip Code)

(760) 438-7400


(212) 582-1199
(Registrant’s telephone number, including area code)

NTN Buzztime, Inc.
6965 El Camino Real, Suite 100-Box 517, Carlsbad, California
(Former name and former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading Symbol(s)symbol
 
Name of each exchange on which registered
Common Stockstock, $0.005 par value per share NTNBTX NYSE American


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES [X] NO [  ]

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every interactive data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [  ]

Indicate by check mark whether the Registrantregistrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in in Rule 12b-2 of the Exchange Act.

Large accelerated filer[  ]Accelerated filer[  ]
Non-accelerated filer[X]Smaller reporting company[X]
  Emerging growth company[  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES [  ] NO [X]

Yes ☐  No ☒


As of May 18, 2020,13, 2021, the registrant had outstanding 2,936,76941,562,739 shares of common stock, $0.005 par value per share.

 



TABLE OF CONTENTS

  Page
PART I – FINANCIAL INFORMATION

NTN BUZZTIME, INC. AND SUBSIDIARIES

FORM 10-Q

TABLE OF CONTENTS

Item Page
 

PART I – FINANCIAL INFORMATION

 
   
1.Financial Statements 
   
 Condensed Consolidated Balance Sheets as of March 31, 2020 (unaudited) and December 31, 20194
   
 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2020 and 2019 (unaudited)5
   
 Condensed Consolidated Statements of Shareholders’ Equity for the three months ended March 31, 2020 and 2019 (unaudited)6
   
 Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019 (unaudited)7
   
 Notes to Condensed Consolidated Financial Statements (unaudited)8
   
2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20
   
3.Quantitative and Qualitative Disclosures About Market Risk31
   
4.Controls and Procedures31
   
 

PART II – OTHER INFORMATION

 
   
1.Legal Proceedings32
   
1A.Risk Factors32
   
2.Unregistered Sales of Equity Securities and Use of Proceeds34
   
3.Defaults Upon Senior Securities34
   
4.Mine Safety Disclosures34
   
5.Other Information34
   
6.Exhibits35
   
 Signatures36

Disclosure Required Under the SEC’s Order dated March 25, 2020

The Securities and Exchange Commission, or the SEC, issued an Order under Section 36 of the Securities Exchange Act of 1934 Modifying Exemptions From the Reporting and Proxy Delivery Requirements for Public Companies, dated March 25, 2020 (Release No. 34-88465), or the Order, which provides conditional relief to registrants subject to the reporting requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 that are unable to meet a filing deadline due to circumstances related to COVID-19.

On April 21, 2020, NTN Buzztime, Inc. (“we,” “us,” or “our”) filed a Current Report on Form 8-K (the “April 21 8-K”) with the SEC disclosing its intention to rely on the Order with respect to this Quarterly Report on Form 10-Q. As stated in that Form 8-K, we experienced, and continue to experience, significant disruptions to our business and operations due to circumstances related to COVID-19, and we were unable to file this report on a timely basis. Among other factors that contributed to us requiring additional time to prepare and finalize this report, we reduced the number of our employees significantly, including a portion of our finance staff, all of our personnel have been and continue to be working remotely, and we rely on third parties to perform analyses and other services related to the preparation of our financial statements, and those third parties also experienced, and continue to experience, disruptions to their operations due to circumstances related to COVID-19.

PART I – FINANCIAL INFORMATION

Item 1.Financial Statements.

NTN BUZZTIME, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value amount)

  

March 31,

2020

  

December 31,

2019

 
ASSETS        
Current Assets:        
Cash and cash equivalents $2,221  $3,209 
Restricted cash  50   50 
Accounts receivable, net of allowances of $838 and $354, respectively  383   1,195 
Site equipment to be installed  856   1,090 
Prepaid expenses and other current assets  755   526 
Total current assets  4,265   6,070 
Restricted cash, long-term  150   150 
Operating lease right-of-use assets  2,002   2,101 
Fixed assets, net  2,489   2,822 
Software development costs, net of accumulated amortization of  $2,735 and $3,341, respectively  1,749   1,915 
Deferred costs  239   274 
Goodwill  -   696 
Other assets  120   97 
Total assets $11,014  $14,125 
         
LIABILITIES AND SHAREHOLDERS’ EQUITY        
Current Liabilities:        
Accounts payable $787  $835 
Accrued compensation  236   588 
Accrued expenses  237   490 
Sales taxes payable  19   131 
Income taxes payable  8   3 
Current portion of long-term debt, net  1,990   2,739 
Current portion of obligations under operating leases  385   409 
Current portion of obligations under financing leases  21   21 
Current portion of deferred revenue  383   460 
Other current liabilities  286   419 
Total current liabilities  4,352   6,095 
Long-term obligations under operating leases  2,782   2,891 
Long-term obligations under financing leases  15   20 
Long-term deferred revenue  1   2 
Other liabilities  15   26 
Total liabilities  7,165   9,034 
         
Shareholders’ Equity        
Series A 10% cumulative convertible preferred stock, $0.005 par value, $156 liquidation preference, 156 shares authorized, issued and outstanding at March 31, 2020 and December 31, 2019  1   1 
Common stock, $0.005 par value, 15,000 shares authorized at March 31, 2020 and December 31, 2019; 2,926 and 2,901 shares issued at March 31, 2020 and December 31, 2019, respectively  15   14 
Treasury stock, at cost, 10 shares at March 31, 2020 and December 31, 2019  (456)  (456)
Additional paid-in capital  136,800   136,721 
Accumulated deficit  (132,675)  (131,457)
Accumulated other comprehensive income  164   268 
Total shareholders’ equity  3,849   5,091 
         
Total liabilities and shareholders’ equity $11,014  $14,125 

See accompanying notes to unaudited condensed consolidated financial statements.

4

NTN BUZZTIME, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except per share amounts)

(unaudited)

  Three Months Ended March 31, 
  2020  2019 
       
Revenue from contracts with customers        
Subscription revenue $1,999  $3,833 
Hardware revenue  16   205 
Other revenue  379   794 
Total revenue from contracts with customers  2,394   4,832 
Operating expenses:        
Direct operating costs (includes depreciation and amortization  of $461 and $651, respectively)  950   1,484 
Selling, general and administrative  3,080   3,468 
Impairment of capitalized software  138   1 
Impairment of goodwill  662   - 
Depreciation and amortization (excluding depreciation and amortization included in direct operating costs)  85   96 
Total operating expenses  4,915   5,049 
Operating loss  (2,521)  (217)
Other income (expense), net  1,284   (85)
Loss before income taxes  (1,237)  (302)
Benefit (provision) for income taxes  19   (11)
Net loss  (1,218)  (313)
         
Net loss per common share - basic and diluted $(0.42) $(0.11)
         
Weighted average shares outstanding - basic and diluted  2,901   2,866 
         
Comprehensive loss        
Net loss $(1,218) $(313)
Foreign currency translation adjustment  (104)  33 
Total comprehensive loss $(1,322) $(280)

See accompanying notes to unaudited condensed consolidated financial statements.

NTN BUZZTIME, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

For the three months ended March 31, 2020 and 2019 (unaudited)

(in thousands)

  

Series A Cumulative

Convertible Preferred

Stock

  Common Stock  Treasury  

Additional

Paid-in

  Accumulated  Accumulated Other Comprehensive    
  Shares  Amount  Shares  Amount  Stock  Capital  Deficit  Income  Total 
                            
Balances at January 1, 2020  156  $1   2,901  $14  $(456) $136,721  $(131,457) $268  $5,091 
Foreign currency translation adjustment  -   -   -   -   -   -   -   (104)  (104)
Net loss  -   -   -   -   -   -   (1,218)  -   (1,218)
Issuance of common stock upon vesting of                                    
restricted stock units, net of shares withheld for payroll taxes  -   -   3   -   -   (3)  -   -   (3)
Issuance of common stock in lieu of                                    
cash compensation, net of shares withheld for payroll taxes  -   -   22   1   -   43   -   -   44 
Non-cash stock based compensation  -   -   -   -   -   39   -   -   39 
Balances at March 31, 2020      156  $           1   2,926  $    15  $(456) $136,800  $(132,675) $        164  $3,849 

  Series A Cumulative Convertible Preferred Stock  Common Stock  Treasury  

Additional

Paid-in

  Accumulated  Accumulated Other Comprehensive    
  Shares  Amount  Shares  Amount  Stock  Capital  Deficit  Income  Total 
                            
Balances at January 1, 2019  156  $1   2,875  $14  $(456) $136,552  $(129,394) $200  $6,917 
Foreign currency translation adjustment  -   -   -   -   -   -   -   33   33 
Net loss  -   -   -   -   -   -   (313)  -   (313)
Issuance of common stock upon vesting of                                    
restricted stock units, net of shares withheld for payroll taxes  -   -   3   -   -   (5)  -   -   (5)
Non-cash stock based compensation  -   -   -   -   -   59   -   -   59 
Balances at March 31, 2019  156  $      1   2,878  $    14  $(456) $136,606  $(129,707) $        233  $6,691 

See accompanying notes to unaudited condensed consolidated financial statements.

6

NTN BUZZTIME, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(unaudited)

  For the three months ended March 31, 
  2020  2019 
Cash flows (used in) provided by operating activities:        
Net loss $(1,218) $(313)
Adjustments to reconcile net loss to net cash provided by operating activities:        
Depreciation and amortization  546   747 
Provision for doubtful accounts  189   30 
Amortization of operating lease right-of-use-assets  73   72 
Common stock issued for compensation in lieu of cash payment  61   - 
Stock-based compensation  39   59 
Gain of asset sale  (1,265)  - 
Loss from the disposition of assets  188   9 
Impairment of capitalized software  138   1 
Impairment of goodwill  662   - 
Amortization of debt issuance costs  3   3 
Changes in assets and liabilities:        
Accounts receivable  723   264 
Site equipment to be installed  1   87 
Operating lease liabilities  (106)  (28)
Prepaid expenses and other assets  (254)  58 
Accounts payable and accrued liabilities  (765)  2 
Income taxes payable  7   10 
Deferred costs  34   (3)
Deferred revenue  (77)  (184)
Other liabilities  (144)  (34)
Net cash (used in) provided by operating activities  (1,165)  780 
Cash flows used in investing activities:        
Capital expenditures  (19)  (41)
Capitalized software development expenditures  (121)  (355)
Net cash used in investing activities  (140)  (396)
Cash flows provided by (used in) financing activities:        
Proceeds from the sale of assets, net  1,166   - 
Payments on long-term debt  (750)  (250)
Debt issuance costs on long-term debt  (3)  - 
Principal payments on finance leases  (5)  (18)
Payroll tax remitted on net share settlement of equity awards  (20)  (5)
Net cash provided by (used in) financing activities  388   (273)
Effect of exchange rate on cash and cash equivalents  (71)  19 
Net (decrease) increase in cash, cash equivalents and restricted cash  (988)  130 
Cash, cash equivalents and restricted cash at beginning of period  3,409   2,786 
Cash, cash equivalents and restricted cash at end of period $2,421  $2,916 
         
Supplemental disclosures of cash flow information:        
Cash paid during the period for:        
         
Interest $37  $71 
         
Income taxes $-  $1 
Supplemental disclosure of non-cash investing and financing activities:        
         
Site equipment transferred to fixed assets $66  $268 
         
Initial measurement of operating lease right-of-use assets and liabilities $-  $3,458 
         
Reconciliation of cash, cash equivalents and restricted cash at end of period:        
Cash and cash equivalents $2,221  $2,666 
Restricted cash  50   50 
Restricted cash, long-term  150   200 
Total cash, cash equivalents and restricted cash at end of period $2,421  $2,916 

See accompanying notes to unaudited condensed consolidated financial statements.

NTN BUZZTIME, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1)BASIS OF PRESENTATION

Description of Business

NTN Buzztime, Inc. (the “Company”) was incorporated in Delaware in 1984 as Alroy Industries and changed its corporate name to NTN Communications, Inc. in 1985. The Company changed its name to NTN Buzztime, Inc. in 2005 to better reflect the growing role of the Buzztime consumer brand.

The Company delivers interactive entertainment and innovative technology, including performance analytics, to help its customers acquire, engage and retain its patrons. The Company’s tablets and technology offer engaging solutions to establishments with guests who experience dwell time, such as in bars, restaurants, casinos and senior living centers. Casual dining venues subscribe to the Company’s customizable solution to differentiate themselves via competitive fun by offering guests trivia, card, sports and arcade games. The Company’s platform creates connections among the players and venues, and amplifies guests’ positive experiences, and its in-venue TV network creates one of the largest digital out of home advertising audiences in the United States and Canada. The Company also continues to support its legacy network product line, which it calls its Classic platform.

The Company generates revenue by charging subscription fees for its service to network subscribers, by leasing tablet platform equipment to certain network subscribers, by selling tablet platform equipment, by hosting live trivia events, by selling advertising aired on in-venue screens and as part of customized games, by licensing its content for use with third-party equipment, from providing professional services (such as developing certain functionality within the Company’s platform for customers), and from pay-to-play arcade games.

At March 31, 2020, 1,396 venues in the U.S. and Canada subscribed to the Company’s interactive entertainment network. See Note 2 for more information regarding the impact of COVID-19 on these venues and the Company’s subscription revenues.

Basis of Accounting Presentation

The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments that are necessary, which are of a normal and recurring nature, for a fair presentation for the periods presented of the financial position, results of operations and cash flows of the Company and its wholly-owned subsidiaries: IWN, Inc., IWN, L.P., Buzztime Entertainment, Inc., NTN Wireless Communications, Inc., NTN Software Solutions, Inc., NTN Canada, Inc., and NTN Buzztime, Ltd., all of which, other than NTN Canada, Inc., are dormant subsidiaries. All significant intercompany transactions have been eliminated in consolidation.

These condensed consolidated financial statements should be read with the audited consolidated financial statements and notes thereto contained in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2019. The accompanying condensed balance sheet as of December 31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be anticipated for the entire year ending December 31, 2020, or any other period.

Reclassifications

Certain reclassifications have been made to the prior period’s financial statements to conform to the current period presentation. These reclassifications had no effect on previously reported results of operations or retained earnings.

(2)COVID-19 UPDATE

The negative impact of the COVID-19 pandemic on the restaurant and bar industry was abrupt and substantial, and the Company’s business, cash flows from operations and liquidity suffered, and continues to suffer, materially as a result. In many jurisdictions, including those in which the Company has many customers and prospective customers, restaurants and bars have been ordered by the government to shut down or close all on-site dining since the latter half of March 2020. At its peak, approximately 70% of the Company’s customers requested that their subscriptions to the Company’s services be temporarily suspended. As governmental orders and restrictions impacting restaurants and bars are eased or lifted, the Company expects the temporary subscription suspensions to end, however, even in jurisdictions in which such orders and restrictions are eased or lifted, the Company’s customers could request to continue their subscription suspensions if, for example, such customers choose not to re-open despite being permitted to do so. The Company has experienced material decreases in subscription revenue, advertising revenue and cash flows from operations, which it expects to continue for at least as long as the restaurant and bar industry continues to be negatively impacted by the COVID-19 pandemic, and which may continue thereafter if restaurants and bars seek to reduce their operating costs or are unable to re-open even if restrictions within their states are eased or lifted. The Company cannot predict with certainty whether, when or the manner in which the impact of the pandemic will improve, including when restaurants will be permitted to offer on-site dining or when bars will be permitted to re-open or to what degree, when the Company’s customers will re-open, or if they will subscribe to the Company’s service if and when they do, or if and when there will be a resurgence in COVID-19 transmission or infection after the easing or lifting of stay-at-home orders, and if three is, the impact of such resurgence on the Company’s business. Similarly, the Company cannot predict with certainty the duration of the negative effects of the pandemic on its business and liquidity, however, unless in the very near term the Company’s subscription revenue, advertising revenue and cash flows from operations return to pre-pandemic levels and/or the Company raises substantial capital, the amount of time and the amount of cash the Company has to maintain operations and sustain the negative effects of the pandemic is very limited. See Item 2 “—Liquidity and Capital Resources,” and “Item 1A. Risk Factors” in Part II of this report for additional information regarding the impact of the pandemic on our business and outlook.

While the Company expects the effects of COVID-19 to negatively impact its future results of operations, cash flows and financial position, the current level of uncertainty over the economic and operational impacts of COVID-19 means the related financial impact cannot be reasonably estimated at this time. The Company’s consolidated financial statements reflect estimates and assumptions made by management that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, if any, at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting periods presented. Such estimates and assumptions affect, among other things, the allowance for doubtful accounts, site equipment to be installed, fixed assets, capitalized software development, goodwill and right-of-use assets. Events and changes in circumstances arising after the issuance of the financial statements as of and for the three months ended March 31, 2020, including those resulting from the impacts of COVID-19, will be reflected in management’s estimates for future periods

(3)going concern uncertainty

In connection with preparing its financial statements as of and for the three months ended March 31, 2020, the Company’s management evaluated whether there are conditions or events, considered in the aggregate, that are known and reasonably knowable that would raise substantial doubt about the Company’s ability to continue as a going concern through twelve months after the date that such financial statements are issued. During the three months ended March 31, 2020, the Company incurred a net loss of $1,218,000, and the Company’s current liabilities exceeded its current assets at March 31, 2020 by $87,000. As of March 31, 2020, the Company had $2,221,000 of unrestricted cash and total debt outstanding of $2,000,000, which was the outstanding principal balance of the Company’s term loan with Avidbank. Under the terms of the amendment to the Company’s loan and security agreement that the Company entered into with Avidbank on March 12, 2020, during 2020, the Company will be required to make monthly payments that, if made in accordance with their terms, will result in the Company paying off the term loan by December 31, 2020. See Note 9 for additional information on this term loan.

As discussed further in Note 16, subsequent to March 31, 2020, the Company received $1,625,100 loan (the “PPP Loan”) under the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration. The Company may use funds from the PPP Loan for payroll costs, costs used to continue group health care benefits, mortgage interest payments, rent payments, utility payments, and interest payments on other debt obligations incurred before February 15, 2020. The Company intends to use the entire PPP Loan for qualifying expenses. Under the terms of the PPP, certain amounts of the PPP Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. No assurance is provided that the Company will obtain forgiveness of the PPP Loan in whole or in part.

As a result of the impact of the COVID-19 pandemic on the Company’s business and taking into account its current financial condition and its existing sources of revenue, unless in the very near term the Company’s subscription revenue, advertising revenue and cash flows from operations returns to pre-pandemic levels and/or the Company raises substantial capital, the Company believes it will have sufficient cash resources to pay forecasted cash outlays through October 2020, assuming the Company delivers a significant hardware order as scheduled during the second quarter of 2020, Avidbank does not take actions to foreclose on the Company’s assets in the event the Company becomes out of compliance with its financial covenants, and the Company is able to continue to successfully manage its working capital deficit by managing the timing of payments to its vendors and other third parties.

Based on the factors described above, management concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern through the twelve month period subsequent to the issuance date of these financial statements. Management’s plans for addressing the liquidity shortfall include continuing efforts to raise additional capital through equity financings and alternative sources of debt. However, there can be no assurances that the Company will be able to raise sufficient capital when needed, on acceptable terms, or at all.

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

(4)RESTRICTED CASH

At the commencement date of the Company’s lease for its corporate headquarters on December 1. 2018, the Company’s bank, Avidbank, issued a $250,000 letter of credit to the lessor as security, which amount will be reduced by $50,000 on December 1 of each year beginning on December 1, 2019, provided there has been no default under the lease. Avidbank required the Company to deposit $250,000 in a restricted cash account maintained with the bank, which amount will be reduced as the amount required under the letter of credit is reduced. The Company recorded the $250,000 deposit as restricted cash on its balance sheet, with $50,000 plus any earned interest being recorded in short-term restricted cash and the balance being recorded in long-term restricted cash. The amount deposited in the restricted cash account does not count toward the covenant in the Avidbank loan and security agreement (see Note 9) that requires the Company to have an aggregate amount of unrestricted cash in deposit accounts or securities accounts maintained with Avidbank of not less than $2,000,000 at all times.

(5)asset sale

On January 13, 2020, the Company entered into an asset purchase agreement with Sporcle, Inc., a Delaware corporation (“Sporcle”), pursuant to which the Company agreed to sell to Sporcle all of its assets necessary for Sporcle to conduct the live-hosted knowledge-based trivia events known as Stump! Trivia and OpinioNation for $1,360,000 in gross proceeds. On the closing date of the transaction (January 31, 2020), the Company received $1,260,000. The remaining $100,000 is being held back until the one-year anniversary of the closing date, or January 31, 2021, to satisfy indemnification claims, if any, for which the Company is liable. The hold-back amount is recorded in accounts receivable in the consolidated balance sheet. The Company recorded a net gain of approximately $1,265,000 in January 2020.

(6)Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) No. 606,Revenue from Contracts with Customers. ASC No. 606 provides a five-step analysis in determining when and how revenue is recognized:

1.Identify the contract(s) with customersFinancial Statements (unaudited)
 2.Identify the performance obligations1
 3.Determine the transaction price2
 4.Allocate the transaction price to the performance obligations3
 5.Recognize revenue when the performance obligations have been satisfied

ASC No. 606 requires revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services.

The Company generates revenue by charging subscription fees to partners for access to its 24/7 trivia network, by selling and leasing tablet and hardware equipment for custom usage beyond trivia/entertainment, by selling digital-out-of-home (DOOH) advertising direct to advertisers and on national ad exchanges, by licensing its entertainment and trivia content to other entities, and by providing professional services such as custom game design or development of new platforms on its existing tablet form factor. Up until February 1, 2020, the Company also generated revenue from hosting live trivia events (see Note 5).

In general, when multiple performance obligations are present in a customer contract, the transaction price is allocated to the individual performance obligation based on the relative stand-alone selling prices, and the revenue is recognized when or as each performance obligation has been satisfied. Discounts are treated as a reduction to the overall transaction price and allocated to the performance obligations based on the relative stand-alone selling prices. All revenues are recognized net of sales tax collected from the customer.

Revenue Streams

The Company disaggregates revenue by material revenue stream as follows:

  Three months ended March 31,    
  2020  2019    
  $  % of Total Revenue  $  % of Total Revenue  $ Change  % Change 
Subscription revenue  1,999,000   83.5%  3,833,000   79.3%  (1,834,000)  (47.8)%
Hardware revenue  16,000   0.7%  205,000   4.2%  (189,000)  (92.2)%
Other revenue  379,000   15.8%  794,000   16.5%  (415,000)  (52.3)%
Total    2,394,000   100.0%    4,832,000   100.0%    (2,438,000)  (50.5)%

The following describes how the Company recognizes revenue under ASC No. 606.

Subscription Revenue - The Company recognizes the recurring subscription fees it receives for its services, which includes the Company’s content, over time as customers receive and consume the benefits of such services, the Company’s equipment to access the Company’s content and the installation of the equipment. In general, customers pay for the subscription services during the month in which they receive the services. Due to the timing of providing the services and receiving payment for the services, the Company does not record any unbilled contract asset. Occasionally, a customer will prepay up to one year of services, in which case, the Company will record deferred revenue on the balance sheet related to such prepayment and will recognize the revenue over the time the customer receives the Company’s services. Revenue from installation services is also recorded as deferred revenue and recognized over the longer of the contract term and the expected term of the customer relationship using the straight-line method. The Company has certain contingent performance obligations with respect to repairing or replacing equipment and will recognize any revenue related to the performance of such obligations at the point in time the Company performs them.

Costs associated with installing the equipment are considered direct costs. Costs associated with sales commissions are considered incremental costs for obtaining the contract because such costs would not have been incurred without obtaining the contract. The Company expects to recover both costs through future fees it collects and both costs are recorded in deferred costs on the balance sheet and amortized on a straight-line basis. For installation costs that are of an amount that is less than or equal to the deferred installation revenue for the related contract, the amortization period approximates the longer of the contract term and the expected term of the customer relationship. For any excess costs that exceed the deferred revenue, the amortization period of the excess cost is the initial term of the contract, which is generally one to two years because the Company can still recover that excess cost in the initial term of the contract. The Company amortizes commissions over the longer of the contract term and the expected term of the customer relationship.

Sales-type Lease Revenue – For certain customers that lease equipment under sale-type lease arrangements, the Company recognizes revenue in accordance with ASC No. 842,Leases. Such revenue is recognized at the time of installation based on the net present value of the leased equipment. Interest income is recognized over the life of the lease for customers who have remaining lease payments to make. In the event a customer under a sales-type lease arrangement prepays for the lease in full prior to receiving the equipment under the lease, such amounts are recorded in deferred revenue and recognized as revenue once the equipment has been installed and activated at the customer’s location. The cost of the leased equipment is recognized at the same time as the revenue. The Company does not expect to recognize revenue under sales-type lease arrangements after the year ended December 31, 2019.

Equipment Sales – The Company recognizes revenue from equipment sales at a point in time, which is when control has been transferred to the customer, the customer holds legal title and the customer has significant risks and rewards of ownership. Generally, the Company has determined that any customer acceptance provisions of the equipment is a formality, as the Company has historically demonstrated the ability to produce and deliver similar equipment. If the Company sells equipment with unique specifications, then customer control of the equipment will occur upon customer acceptance as defined in the contract, and revenue will be recognized at that time. Costs associated with the equipment sold is recognized at the same point in time as the revenue.

Advertising Revenue – The Company recognizes advertising revenue either over the time the advertising campaign airs in its customers’ locations or at a point in time by impression. For advertising campaigns that are airing over a specific period of time (regardless of number of impressions), the Company uses the time elapsed output method to measure its progress toward satisfying the performance obligation. When the Company contracts with an advertising agent, the Company shares in the advertising revenue generated with that agent. In these cases, the Company generally recognizes revenue on a net basis, as the agent typically has the responsibility for the relationship with the advertiser and the credit risk. When the Company contracts directly with the advertiser, it will recognize the revenue on a gross basis and will recognize any revenue share arrangement it has with a third party as a direct expense, as the Company has the responsibility for the relationship with the advertiser and the credit risk. Generally, there is no unbilled revenue associated with the Company’s advertising activities.

Content Licensing – The Company licenses content (trivia packages) to a certain customer, who in turn installs the content on its equipment that it sells to its customers. The content license is characterized as a “right to use intellectual property as it exists at the point in time at which the license is granted,” meaning the Company is not expected to undertake activities that affect the intellectual property or any such activities would not affect the intellectual property the customer is using. The content license is considered to be on consignment, and the Company retains title of the licensed content throughout the license period. The Company’s customer has no obligation to pay for the licensed content until the customer sells and installs the content to its customer. Accordingly, the Company recognizes revenue at the point in time when such installation occurs. The Company recognizes costs related to developing the content during the period incurred.

Live-hosted Trivia Revenue – The Company recognizes its live-hosted trivia revenue at a point in time, which is when the event takes place. Some customers host their own trivia events and the Company provides the game materials. In these cases, the Company recognizes the revenue at the point in time the Company sends the game materials to the customer. The Company recognizes related costs at the same point in time the revenue is recognized. Generally, there is no unbilled revenue or deferred revenue associated with live-hosted trivia events. The Company does not expect to recognize live-hosted trivia revenue after January 31, 2020. See Note 5 for more information on the live-hosted trivia product line.

Professional Development Revenue – Depending on the type of development work the Company is performing, the Company will recognize revenue, and associated costs, at the point in time when the Company satisfies each performance obligation, which is generally when the customer can direct the use of, and obtain substantially all of the remaining benefits of the goods or service provided. For services provided over time, the corresponding revenue is generally recognized over the time the Company provides such services. Any payments received before satisfying the performance obligations are recorded as deferred revenue and recognized as revenue when or as such obligations are satisfied. The Company does not have unbilled revenue assets associated with professional development services.

Revenue Concentrations

The Company’s customers predominantly range from small independently operated bars and restaurants to bars and restaurants operated by national chains. This results in diverse venue sizes and locations. As of March 31, 2019, 2,632 venues in the U.S. and Canada subscribed to the Company’s interactive entertainment network, of which approximately 46% were Buffalo Wild Wings corporate-owned restaurants and its franchisees. As of March 31, 2020, the Company’s site count declined to 1,396 venues primarily due to the termination of its agreements with Buffalo Wild Wings corporate-owned restaurants and most of its franchisees in November 2019 in accordance with their terms.

The table below sets forth the approximate amount of revenue the Company generated from Buffalo Wild Wings corporate-owned restaurants and its franchisees during the three months ended March 31, 2020 and 2019, and the percentage of total revenue that such amount represents for such periods:

  

Three months ended

March 31,

 
  2020  2019 
Buffalo Wild Wings revenue $101,719  $1,936,000 
Percent of total revenue  4%  40%

As of March 31, 2020 and December 31, 2019, approximately $178,000 and $158,000, respectively, was included in accounts receivable from Buffalo Wild Wings corporate-owned restaurants and its franchisees.

The geographic breakdown of the Company’s revenue for the three months ended March 31, 2020 and 2019 were as follows:

  

Three months ended

March 31,

 
  2020  2019 
United States $2,249,000  $4,661,000 
Canada  145,000   171,000 
Total revenue $2,394,000  $4,832,000 

Contract Assets and Liabilities

The Company enters into contracts and may recognize contract assets and liabilities that arise from these contracts. The Company recognizes revenue and corresponding cash for customers who auto pay via their bank account or credit card, or the Company recognizes a corresponding accounts receivable for customers the Company invoices. The Company may receive consideration from customers, per the terms of the contract, prior to transferring goods or services to the customer. In such instances, the Company records a contract liability and recognizes the contract liability as revenue when all revenue recognition criteria are met. The table below shows the balance of contract liabilities as of January 1, 2020 and March 31, 2020, including the change during the period.

  Deferred Revenue 
Balance at January 1, 2020 $460,000 
New performance obligations  180,000 
Revenue recognized  (256,000)
Balance at March 31, 2020  384,000 
Less non-current portion  (1,000)
Current portion at March 31, 2020 $383,000 

The Company capitalizes installation costs associated with installing equipment in a customer location and sales commissions as a deferred cost asset on the balance sheet. For installation costs that are of an amount that is less than or equal to the deferred installation revenue for the related contract, the amortization period approximates the longer of the contract term and the expected term of the customer relationship. For any excess installation costs that exceed the deferred revenue, the amortization period of the excess cost is the initial term of the contract, which is generally one to two years because the Company can still recover that excess cost in the initial term of the contract. The Company amortizes commission costs over the longer of the contract term and the expected term of the customer relationship. The table below shows the balance of the unamortized installation cost and sales commissions as of January 1, 2020 and March 31, 2020, including the change during the period.

  Installation Costs  Sales Commissions  Total Deferred Costs 
Balance at January 1, 2020 $187,000  $87,000  $274,000 
Incremental costs deferred  68,000   53,000   121,000 
Deferred costs recognized  (92,000)  (64,000)  (156,000)
Balance at March 31, 2020  163,000   76,000   239,000 

(7)Basic and Diluted Earnings Per Common Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of potential common shares. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares. Stock options, restricted stock units, and other convertible securities are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury method when their effect is dilutive. Options, restricted stock units and convertible preferred stock representing approximately 172,000 and 262,000 shares of common stock were excluded from the computations of diluted net loss per common share for the three months ended March 31, 2020 and 2019, respectively, as their effect was anti-dilutive.

(8)SHAREHOLDERS’ EQUITY

Equity Incentive Plans

The Company’s stock-based compensation plans include the NTN Buzztime, Inc. 2019 Performance Incentive Plan (the “2019 Plan”), the NTN Buzztime, Inc. Amended 2010 Performance Incentive Plan (the “2010 Plan”) and the NTN Buzztime, Inc. 2014 Inducement Plan (the “2014 Plan”). The Company’s board of directors designated its nominating and corporate governance/compensation committee as the administrator of the foregoing plans (the “Plan Administrator”). Among other things, the Plan Administrator selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures, if any, and other provisions of the award.

The 2019 Plan provides for the issuance of up to 240,000 shares of Company common stock. Awards under the 2019 Plan may be granted to officers, directors, employees and consultants of the Company. Stock options granted under the 2019 Plan may either be incentive stock options or nonqualified stock options, have a term of up to ten years, and are exercisable at a price per share not less than the fair market value on the date of grant. As of March 31, 2020, there were stock options to purchase approximately 2,000 shares of common stock and 108,000 restricted stock units outstanding under the 2019 Plan.

As a result of stockholder approval of the 2019 Plan in June 2019, no future grants will be made under the 2010 Plan. All awards that are outstanding under the 2010 Plan will continue to be governed by the 2010 Plan until they are exercised or expire in accordance with the terms of the applicable award or the 2010 Plan. As of March 31, 2020, there were stock options to purchase approximately 32,000 shares of common stock and 18,000 restricted stock units outstanding under the 2010 Plan.

The 2014 Plan provides for the grant of up to 85,000 share-based awards to a new employee as an inducement material to the new employee entering into employment with the Company and expires in September 2024. As of March 31, 2020, there were no equity grants outstanding under the 2014 Plan.

Stock-Based Compensation

The Company records stock-based compensation in accordance with ASC No. 718, Compensation – Stock Compensation. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The fair value of stock options granted is recognized as expense over the requisite service period. Stock-based compensation expense for share-based payment awards is recognized using the straight-line single-option method.

The Company uses the historical stock price volatility as an input to value its stock options under ASC No. 718. The expected term of stock options represents the period of time options are expected to be outstanding and is based on observed historical exercise patterns of the Company, which the Company believes are indicative of future exercise behavior. For the risk-free interest rate, the Company uses the observed interest rates appropriate for the term of time options are expected to be outstanding. The dividend yield assumption is based on the Company’s history and expectation of dividend payouts.

The Company did not grant any stock options and no options were exercised during the three months ended March 31, 2020 or 2019.

The Company estimates forfeitures, based on historical activity, at the time of grant and revised if necessary in subsequent periods if actual forfeiture rates differ from those estimates. Stock-based compensation expense for employees during the three months ended March 31, 2020 and 2019 was $39,000 and $59,000, respectively, and is expensed in selling, general and administrative expenses and credited to the additional paid-in-capital account.

Outstanding restricted stock units (“RSUs”) are settled in an equal number of shares of common stock on the vesting date of the award. An RSU award is settled only to the extent vested. Vesting generally requires the continued employment or service by the award recipient through the respective vesting date. Because RSUs are settled in an equal number of shares of common stock without any offsetting payment by the recipient, the measurement of cost is based on the quoted market price of the stock at the measurement date, which is the grant date. For the three months ended March 31, 2020 and 2019, the Company granted the following awards:

Three months ended RSUs Granted  Weighted averge grant date fair value per RSU  Vesting terms
March 31, 2020  153,000  $2.43  12.5% every three months from grant date over two years
           
March 31, 2019  47,000  $3.72  16.67% on six month anniversary of grant date, then equal monthly installments over following 30 months

The following table shows the number of RSUs that vested and were settled during the three months ended March 31, 2020 and 2019, as well as the number of shares of common stock issued upon settlement. In lieu of paying cash to satisfy withholding taxes due upon the settlement of vested RSUs, an employee may elect to have shares of common stock withheld that would otherwise be issued at settlement, the value of which is equal to the amount of withholding taxes payable.

  Three months ended March 31, 
  2020  2019 
Restricted stock units vested and settled  4,000   4,000 
Common stock issued, net of shares withheld  3,000   3,000 

14

(9)DEBT

Term Loan

In September 2018, the Company entered into a loan and security agreement with Avidbank for a 48-month term loan in the amount of $4,000,000, under which the Company was obligated to make monthly principal payments of approximately $83,000 plus accrued and unpaid interest. In February 2020, the Company made a pre-payment on the term loan of approximately $150,000 following the sale of all of the Company’s assets used to conduct the live-hosted knowledge-based trivia events known as Stump! Trivia and OpinioNation in January 2020 (see Note 5). On March 12, 2020, the Company entered into an amendment to the loan and security agreement. In connection with entering into the amendment, the Company made a $433,000 payment on its term loan, which included the $83,333 monthly principal payment plus accrued interest for March 2020 and a $350,000 principal prepayment, thereby reducing the outstanding principal balance of its term loan to $2,000,000 as of March 31, 2020.

The Company incurred approximately $26,000 of debt issuance costs related to loan and security agreement and its amendment, of which approximately $3,000 was related to the amendment. The debt issuance costs are being amortized to interest expense using the effective interest rate method over the life of the loan. The unamortized balance of the debt issuance costs as of March 31, 2020 and December 31, 2019 was $10,000 and $11,000, respectively, and is recorded as a reduction of long-term debt.

Under the terms of the amendment, the Company’s financial covenants were changed, the maturity date of its term loan was changed from September 28, 2022 to December 31, 2020, and commencing on April 30, 2020, the Company must make principal plus accrued interest payments on the last day of each month, such that its term loan will be repaid by December 31, 2020. The principal payment the Company must make each month will be $125,000 for each of April, May and June, $300,000 for each of July, August, September, October and November, and $125,000 for December.

Under the terms of the original loan and security agreement, the Company’s adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) was required to be at least $1,000,000 for the trailing six-month period as of the last day of each fiscal quarter and the aggregate amount of unrestricted cash it had in deposit accounts or securities accounts maintained with Avidbank must be not less than $2,000,000 at all times.

Under the terms of the amendment, the minimum EBITDA covenant was replaced with a monthly minimum asset coverage ratio covenant, which the Company refers to as the ACR covenant, and the minimum liquidity covenant was amended to provide that the aggregate amount of unrestricted cash the Company has in deposit accounts or securities accounts maintained with Avidbank must be at all times not less than the principal balance outstanding under the term loan. Under the ACR covenant, the ratio of (i) the Company’s unrestricted cash at Avidbank as of the last day of a calendar month plus 75% of its outstanding accounts receivable accounts that are within 90 days of invoice date to (ii) the outstanding principal balance of the term loan on such day must be no less than 1.25 to 1.00. As of March 31, 2020, the Company was in compliance with both of those covenants.

(10)LEASES

On January 1, 2019, the Company adopted ASC No. 842,Leases (“ASC No. 842”). ASC No. 842 primarily requires lessees to recognize at the lease commencement date a lease liability, which is the lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. Lessees and lessors must either (i) apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements or (ii) recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Applying a full retrospective transition approach is not allowed. The Company elected to use the cumulative-effect transition method upon adoption.

ASC No. 842 also allows lessees and lessors to elect certain practical expedients. The Company elected the following practical expedients:

Transitional practical expedients:

The Company need not reassess whether any expired or existing contracts are or contain leases.4
 The Company need not reassess the lease classification for any expired or existing leases (that is, all existing leases that were classified as operating leases in accordance with the previous guidance will be classified as operating leases, and all existing leases that were classified as capital leases in accordance with the previous guidance will be classified as finance leases). 5
The Company need not reassess initial direct costs for any existing leases.

Hindsight practical expedient. The Company elected the hindsight practical expedient in determining the lease term (that is, when considering lessee options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of the Company’s right-of-use assets.
As a lessor, the Company elected to not separate nonlease components from lease components when both of the following are met:

The timing and patterns of transfer for the lease component and nonlease component associated with that lease component are the same; and
The lease component, if accounted for separately, would be classified as an operating lease.

As Lessee

The Company has entered into operating leases for office and production facilities and equipment under agreements that expire at various dates through 2026. Certain of these leases contain renewal provisions and escalating rental clauses and generally require the Company to pay utilities, insurance, taxes and other operating expenses. The Company also has property held under finance leases that expire at various dates through 2021. The Company’s leases do not contain any residual value guarantees or material restrictive covenants.

Upon adoption of ASC No. 842, the Company recognized on its consolidated balance sheet as of January 1, 2019 an initial measurement of approximately $3,458,000 of operating lease liabilities, and approximately $2,336,000 of corresponding operating right-of use assets, net of tenant improvement allowances. The initial measurement of the finance leases under ASC No. 842 did not have a material change from the balances of the finance lease liabilities and assets recorded prior to the adoption of ASC No. 842. There was also no cumulative effect adjustment to retained earnings as a result of the transition to ASC No. 842. The Company recorded the initial recognition of the operating leases as a supplemental noncash financing activity on the accompanying consolidated statement of cash flows. The adoption of ASC No. 842 did not have a material impact on the Company’s consolidated statement of operations.

The tables below show the beginning balances of the operating lease right-of-use assets and liabilities as of January 1, 2019 and the ending balances as of March 31, 2020, including the changes during the periods.

  Operating lease right-of-use assets 
Operating lease right-of use assets at January 1, 2020 $2,101,000 
Amortization of operating lease right-of-use assets  (73,000)
Write-off of right-of-use asset related to asset sale (Note 5)  (26,000)
Operating lease right-of-use assets at March 31, 2020 $2,002,000 

  Operating lease liabilities 
Operating lease liabilities at January 1, 2020 $3,300,000 
Principal payments on operating lease liabilities  (106,000)
Write-off of lease liability related to asset sale (Note 5)  (27,000)
Operating lease liabilities at March 31, 2020  3,167,000 
Less non-current portion  (2,782,000)
Current portion at March 31, 2020 $385,000 

As of March 31, 2020, the Company’s operating leases have a weighted-average remaining lease term of 6.0 years and a weighted-average discount rate of 7.25%. The maturities of the operating lease liabilities are as follows:

  As of 
  March 31, 2020 
2020 $450,000 
2021  613,000 
2022  634,000 
2023  655,000 
2024  670,000 
Thereafter  931,000 
Total operating lease payments  3,953,000 
Less imputed interest  (786,000)
Present value of operating lease liabilities $3,167,000 

For the three months ended March 31, 2020 and 20198, total lease expense under operating leases was approximately $134,000 and $135,000, respectively, and was recorded in selling, general and administrative expenses.

The tables below show the beginning balances of the finance lease right-of-use assets and liabilities as of January 1, 2020 and the ending balances as of March 31, 2020, including the changes during the periods. The Company’s finance lease right-of-use assets are included in “Fixed assets, net” on the accompanying consolidated balance sheet.

  Finance lease right-of-use assets 
Finance lease right-of use assets at January 1, 2020 $41,000 
Depreciation of finance lease  right-of-use assets  (5,000)
Finance lease right-of-use assets at March 31, 2020 $36,000 

  Finace lease liabilities 
Finance lease liabilities at January 1, 2020 $41,000 
Principal payments on finance lease liabilities as of March 31, 2020  (5,000)
Finance lease liabilities at March 31, 2020  36,000 
Less non-current portion  (21,000)
Current portion at March 31, 2020 $15,000 

As of March 31, 2020, the Company’s finance leases have a weighted-average remaining lease term of 1.7 years and a weighted-average discount rate of 5.52%. The maturities of the finance lease liabilities are as follows:

  As of 
  March 31, 2020 
2020  17,000 
2021  21,000 
Total Finance lease payments  38,000 
Less imputed interest  (2,000)
Present value of Finance lease liabilities $36,000 

For the three months ended March 31, 2020 and 2019, total lease costs under finance leases were approximately $6,000 and $22,000, respectively.

As Lessor

ASC No. 842 did not make fundamental changes to lease accounting guidance for lessors. Therefore there was no financial statement impact due to the adoption of ASC No. 842. As a lessor, the Company has two types of customer contracts that involve leases: right-to-use operating leases and sales-type leases.

Right-to-use operating leases. Certain customers enter into contracts to obtain subscription services from the Company, which includes the Company’s content (nonlease component) and equipment installed in the customer locations so the customer can access the content (lease component). The timing and pattern of the transfer of both the subscription services and the equipment are the same, that is, the Company’s subscription services are made available to its customer at the same time as the equipment is installed. Additionally, the Company has determined that the lease component of these customer contracts is an operating lease. Accordingly, the Company has concluded that these contracts qualify for the practical expedient permitted under ASC No. 842 to not separate the nonlease component from the related lease component. Instead, the Company treats the combined component as a single performance obligation under Topic 606,Revenue from Contracts with Customers, as the Company has concluded that the nonlease component (subscription services) is the predominant component of the combined component.

Sales-type leases. As with the contracts under right-of-use operating leases, certain customers enter into contracts to obtain subscription services from the Company, which includes the Company’s content (nonlease component) and equipment installed in the customer locations so the customer can access the content (lease component). Generally, the equipment lease term is for three years and the customer prepays its lease in full. After the lease term, the lessee may purchase the equipment for a nominal fee or lease new equipment. Although the timing and pattern of the transfer of both the subscription services and the equipment may be the same, the provisions of the contract related to the equipment results in a sales-type lease, and therefore, the Company cannot treat both the nonlease component and the lease component as a combined component. Accordingly, the nonlease component is accounted for under Topic 606 and the sales-type lease is accounted for under Topic 842 and separately disaggregated on the Company’s statement of operations. The Company does not anticipate entering into any sales-type lease arrangements after December 31, 2019.

(11)DISPOSITION OF SITE EQUIPMENT TO BE INSTALLED AND FIXED ASSETS

Site equipment to be installed consists of fixed assets related to the Company’s tablet platform that have not yet been placed in service and are stated at cost. These assets remain in site equipment to be installed until they are deployed at the Company’s customer sites. For tablet platform customers that are under sales-type lease arrangements, the cost of the equipment is recognized in direct costs upon installation. For all other tablet platform customers, the cost of the equipment is reclassified to fixed assets upon installation and depreciated over its estimated useful life. The Company evaluates the recoverability of site equipment to be installed and fixed assets for impairment whenever events or circumstances indicate that the carrying amounts of such assets may not be recoverable. Recoverability is measured by comparing the carrying amount of an asset or asset group to estimated undiscounted future net cash flows expected to be generated. If the carrying amount of the asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary.

Based on the Company’s on-going review of its equipment in site equipment to be installed and in fixed assets, the Company determined that it would no longer be deploying some of the Company’s older tablets, related cases and card readers. Accordingly, the Company wrote off approximately $188,000 related to this equipment during the three months ended March 31, 2020. The expense associated with this write-off is in direct operating costs in the Company’s consolidated statement of operations. Due to uncertainty of the longer-term impact COVID-19 will have on the Company’s business, the Company did not record any additional equipment write-offs for the three months ended March 31, 2020, but will continue to monitor the recoverability of these assets and recognize any additional write-offs during the period in which it determines that impairment exists.

(12)SOFTWARE DEVELOPMENT COSTS

The Company capitalizes costs related to developing certain software programs in accordance with ASC No. 350,Intangibles – Goodwill and Other. When the Company deploys the programs, it begins to recognize costs related to the programs on a straight-line basis over the programs’ estimated useful lives, generally two to three years. Amortization expense relating to capitalized software development costs totaled $149,000 and $97,000 for the three months ended March 31, 2020 and 2019, respectively. As of March 31, 2020 and December 31, 2019, approximately $144,000 and $177,000, respectively, of capitalized software costs were not subject to amortization as the development of various software projects was not complete.

The Company performed its quarterly review of software development projects for the three months ended March 31, 2020 and 2019, and determined to abandon various software development projects that the Company concluded were no longer a current strategic fit or for which it determined that the marketability of the content had decreased due to obtaining additional information regarding the specific industry for which the content was intended. As a result, the Company recognized an impairment of $138,000 and $1,000 for the three months ended March 31, 2020 and 2019, respectively. Impairment of capitalized software is shown separately on the Company’s consolidated statement of operations. Due to uncertainty of the longer-term impact COVID-19 will have on the Company’s business, the Company did not record any additional software development impairment charges for the three months ended March 31, 2020, but will continue to monitor the recoverability of these assets and recognize any additional write-offs during the period in which it determines that impairment exists.

(13)GOODWILL

The Company’s goodwill balance of $696,000 as of December 31, 2019 relates to the excess of costs over the fair value of assets the Company acquired in 2003 related to its Canadian business (the “Reporting Unit”). In the Company’s evaluation of impairment indicators as of March 31, 2020, it determined that the uncertainty relating to COVID-19’s impact on the Reporting Unit’s future operating results represented an indicator of impairment. Accordingly, the Company compared the estimated fair value of the Reporting Unit to its carrying value at March 31, 2020, determined that a full impairment loss was warranted and recognized an impairment charge of $662,000 for the three months ended March 31, 2020. There was no goodwill impairment recorded for the three months ended March 31, 2019.

In addition to the impairment loss recognized, fluctuations in the amount of goodwill shown on the accompanying balance sheets can occur due to changes in the foreign currency exchange rates used when translating NTN Canada’s financial statement from Canadian dollars to US dollars during consolidation. The following table shows the changes in the carrying amount of goodwill for the three months ended March 31, 2020.

Goodwill balance at January 1, 2020 $696,000 
Effects of foreign currency  (34,000)
Goodwill impairment  (662,000)
Goodwill balance at March 31, 2020 $- 

(14)ACCUMULATED OTHER COMPREHENSIVE INCOME

The United States dollar is the Company’s functional currency, except for its operations in Canada where the functional currency is the Canadian dollar. The financial position and results of operations of the Company’s foreign subsidiaries are measured using the foreign subsidiary’s local currency as the functional currency. In accordance with ASC No. 830,Foreign Currency Matters, revenues and expenses of the Company’s foreign subsidiaries have been translated into U.S. dollars using the average exchange rates during the reporting period, and the assets and liabilities of such subsidiaries have been translated using the period end exchange rate. Accumulated other comprehensive income includes the accumulated gains or losses from these foreign currency translation adjustments. As of March 31, 2020 and December 31, 2019, $164,000 and $268,000 of foreign currency translation adjustments were recorded in accumulated other comprehensive income, respectively.

(15)RECENT ACCOUNTING PRONOUNCEMENTS

In December 2019, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2019-12,Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes.This ASU enhances and simplifies various aspect of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year and interim-period accounting for enacted changes in tax law. The amendment will be effective for public companies with fiscal years beginning after December 15, 2020, (which will be January 1, 2021 for the Company); early adoption is permitted. The Company is currently assessing the impact of this pronouncement to its consolidated financial statements.

In November 2019, the FASB issued ASU No. 2019-08,Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) (“ASU No. 2019-08”). This ASU requires that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. The amount recorded as a reduction of the transaction price is required to be measured on the basis of the grant-date fair value of the share-based payment award in accordance with Topic 718. The grant date is the date at which a grantor (supplier) and a grantee (customer) reach a mutual understanding of the key terms and conditions of a share-based payment award. The classification and subsequent measurement of the award are subject to the guidance in Topic 718 unless the share-based payment award is subsequently modified and the grantee is no longer a customer. The standard is effective for fiscal years beginning after December 15, 2019 (which was January 1, 2020 for the Company). The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

In November 2018, the FASB issued ASU No. 2018-18,Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This ASU requires certain transactions between participants in a collaborative arrangement to be accounted for as revenue under the new revenue standard when the participant is a customer. The standard is effective for fiscal years beginning after December 15, 2019 (which was January 1, 2020 for the Company). The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15,Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for fiscal years beginning after December 15, 2019 (which was January 1, 2020 for the Company) and can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13,Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This ASU modifies certain disclosure requirements on fair value measurements. The standard is effective for fiscal years beginning after December 15, 2019 (which was January 1, 2020 for the Company). The adoption of this ASU did not have a significant impact on the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13,Measurement of Credit Losses on Financial Instruments, which supersedes current guidance requiring recognition of credit losses when it is probable that a loss has been incurred. The ASU requires an entity to establish an allowance for estimated credit losses on financial assets, including trade and other receivables, at each reporting date. This ASU will result in earlier recognition of allowances for losses on trade and other receivables and other contractual rights to receive cash. For smaller reporting companies, the effective date for this standard has been delayed and will be effective for fiscal years beginning after December 15, 2022 (which will be January 1, 2023 for the Company). The Company is evaluating the impact that the adoption of this standard will have on its consolidated financial statements.

(16)SUBSEQUENT EVENT

Paycheck Protection Program Loan

On April 18, 2020, the Company issued a note in the principal amount of $1,625,100 to Level One Bank evidencing the PPP Loan the Company received under CARES Act administered by the U.S. Small Business Administration.

The PPP Loan matures on April 18, 2022 and bears interest at a rate of 1.0% per annum. The Company must make monthly interest only payments beginning on November 18, 2020. One final payment of all unforgiven principal plus any accrued unpaid interest is due at maturity. Under the terms of the PPP, the Company may prepay the PPP Loan at any time with no prepayment penalties. The Company may use funds from the PPP Loan for payroll costs, costs used to continue group health care benefits, mortgage interest payments, rent payments, utility payments, and interest payments on other debt obligations incurred before February 15, 2020. The Company intends to use the entire PPP Loan for qualifying expenses. Under the terms of the PPP, certain amounts of the PPP Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. No assurance is provided that the Company will obtain forgiveness of the loan in whole or in part.

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
29
Item 3.38
Item 4.38
PART II – OTHER INFORMATION
Item 1.39
Item 1A.39
Item 6.40
41

CAUTION CONCERNING


In this report, “Brooklyn Inc.” refers to Brooklyn ImmunoTherapeutics, Inc. (formerly known as NTN Buzztime, Inc.) and “Brooklyn LLC” refers to Brooklyn ImmunoTherapeutics LLC, a wholly owned subsidiary of Brooklyn Inc. All references to “our company,” “we,” “us” or “our” mean Brooklyn Inc. and its subsidiary Brooklyn LLC, unless stated otherwise or the context otherwise requires.


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report and the documents incorporated by reference herein, if any, containcontains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995, or the Forward-Looking Statements Safe Harbor, as codified in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts could be deemed forward-looking statements. We have tried, whenever possible, to identify these statements by using words such as “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” or words of similar meaning, or future or conditional verbs, such as “may,” “will,” “should,” “could,” “aims,” “intends” or “projects,” and similar expressions, whether in the negative or the affirmative. Forward-looking statements reflect management’s beliefs and assumptions, are all based on currently available operating, financial and competitive information and are subject to various risks and uncertainties. Forward-looking statements by their nature address matters that are, to different degrees, subject to risks and uncertainties that could cause actual results to differ materially and adversely from those expressed in any forward-looking statement. For us, particular
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in our forward-looking statements. We have included important factors that might cause or contribute to such differences include (1) our ability to raise substantial capital in the very near-termcautionary statements included, or incorporated by reference, in this report, particularly in “Risk Factors,” that we believe could cause actual results or events to allow us to maintain operationsdiffer materially from our forward-looking statements. You should also carefully review the risk factors and sustain the negative impact of the COVID-19 pandemic on our business and financial condition, and if we are able to sustain such impact, our ability to recover from the impact; (2) our ability to successfully manage our liquidity and our working capital deficit by managing the timing of payments to our third parties; (3) our ability to comply with our financial covenants in our loan and security agreement with Avidbank and its right to declare a default if we do not, which could lead to all payment obligations becoming immediately due and payable and which could lead to a foreclosure on our assets; (4) when, and the extent to which, the negative impact of the pandemic will improve, including when restaurants will be permitted to offer on-site dining or when bars will be permitted to re-open and to what degree, when our customers will re-open, or if they will subscribe to our service if and when they do; (5) the negative impact that measures we implemented and may implement to reduce our operating expenses and planned capital expenses (including investments in our business) may have on our ability to effectively manage and operate our business; (5) our ability to maintain or grow our revenue; (6) our ability to compete effectively within the highly competitive interactive games, entertainment and marketing services industries, including our ability to successfully commercially launch attractive product offerings, and the impact of new products and technological change, especially in the mobile and wireless markets, on our operations and competitiveness; (7) our ability to adequately protect our proprietary rights and intellectual property; and (8) the other risks and uncertaintiescautionary statements described in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (our “2019 10-K”), and described in other documents we file from time to time with the Securities and Exchange Commission, or SEC, includingspecifically under “Risk Factors” in Item 8.01 of our Current ReportsReport on Form 8-K8‑K filed with the SEC on March 30, 2020 and April 21, 2020, this report and our other Current Reports and Quarterly Reports.

Readers are urged not to place undue reliance on the forward-looking statements in this report or incorporated by reference herein, which speak only as of the date of this report. We are including this cautionary note to make applicable, and take advantage of, the safe harbor provisions of the Forward-Looking Statements Safe Harbor.

We historically have operated in a continually changing business environment. The country and both the global economy generally and, for our purposes, the U.S. economy face profound dislocations and unprecedented uncertainty as a result of the COVID-19 pandemic. The full extent to which the COVID-19 pandemic will, directly or indirectly, impact our business, results of operations and financial condition is currently highly uncertain, including due to factors that currently are also highly uncertain, including a resurgence in COVID-19 transmission or infection after the easing or lifting of stay-at-home restrictions, actions required or recommended to contain or treat COVID-19, and the direct and indirect economic impact of COVID-19.

We believe that the expectations reflected in forward-looking statements in this report or incorporated herein by reference are based upon reasonable assumptions at the time made. However, given the risks and uncertainties, you should not rely on any forward- looking statements as a prediction of actual results, developments or other outcomes. You should read these forward-looking statements with the understanding that we may be unable to achieve projected results, developments or other outcomes and that actual results, developments or other outcomes may be materially different from what we expect. You are cautioned not to place undue reliance on these forward-looking statements.

May 11, 2021.

We intend forward-looking statements to speak only as of the time they are made. Except as required by law, we do not undertake, and expressly disclaim any obligation, to disseminate, after the date hereof, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.



Table of Contents

BROOKLYN IMMUNOTHERAPEUTICS, INC.
 CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)


 
March 31,
    December 31,  
  2021  2020 
Assets (Unaudited)
    
Current Assets:      
Cash $8,409,938  $1,630,455 
Subscription receivable  24,918   - 
Tax receivable  28,490   - 
Prepaid expenses and other current assets  250,243   102,322 
Total Current Assets  8,713,589   1,732,777 
         
Long-Term Assets:        
Property and equipment, net  568,943   594,106 
Right of use assets - operating leases  2,023,263   2,092,878 
Goodwill  2,043,747   2,043,747 
In process research and development  6,860,000   6,860,000 
Security deposits and other assets  488,534   453,252 
Total Assets $20,698,076  $13,776,760 
         
Liabilities and Stockholders’ Deficit        
Current Liabilities:        
Accounts payable $1,812,017  $1,275,223 
Accrued expenses  1,160,344   1,051,020 
Loans payable  410,000   410,000 
PPP loan, current  232,235   115,972 
Current portion of lease liability  287,359   273,217 
Total Current Liabilities  3,901,955   3,125,432 
         
Long-Term Liabilities:        
Contingent consideration  19,290,000   20,110,000 
Lease liability, non-current  1,826,863   1,905,395 
PPP loan, non-current  77,670   193,933 
Other liabilities  22,863   22,863 
Total Liabilities  25,119,351   25,357,623 
         
Commitments and contingencies        
         
Stockholders’ Deficit:        
Class A membership units  -   23,202,005 
Class B membership units  -   1,400,000 
Class C membership units  -   1,000,000 
Common units  -   197,873 
Common stock, $0.005 par value; 100,000,000 shares authorized; 41,505,998 shares issued and outstanding as of March 31, 2021, and no shares issued and outstanding as of December 31, 2020  207,530   - 
Additional paid-in capital  50,453,489   - 
Series A preferred stock  781   - 
Accumulated deficit  (55,083,075)  (37,380,741)
Total Stockholders’ Deficit  (4,421,275)  (11,580,863)
Total Liabilities and Stockholders’ Deficit $20,698,076  $13,776,760 

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

 Three Months Ended March 31, 
  2021  2020 
       
Operating Expenses:      
Research and development 
$
1,519,633
  $(38,971)
General and administrative  
1,636,557
   
1,053,505
 
Transaction costs  
5,765,407
   - 
Change in fair value of contingent consideration  
(820,000
)
  - 
Total operating expenses  
8,101,597
   
1,014,534
 
Loss from operations  
(8,101,597
)
  (1,014,534)
Other Expenses:        
Other expense, net  
(2,564
)
  (4,678)
Loss on sales of NTN assets  
(9,598,173
)
  - 
Total other expenses  
(9,600,737
)
  
(4,678
)
Net loss attributable to common stockholders $(17,702,334) $(1,019,212)
Basic and diluted net loss per share attributable to common stockholders $(0.64) $(0.06)
Basic and diluted weighted average number of shares outstanding  27,799,415   17,501,813 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEMBERS’ AND STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
     Membership Equity  Common Stock        
  
Series A
Preferred Stock
  Class A  Class B  Class C  Common  Shares  Amount  
Additional
Paid-in Capital
  
Accumulated
Deficit
  Total
Stockholders’
Equity (Deficit)
 
Balance - January
1, 2021
 $-  $23,202,005  $1,400,000  $1,000,000  $197,873   -  $-  $-  $(37,380,741) $(11,580,863)
Brooklyn rights offerings membership units  -   10,500,000   -   -   -   -   -   -   -   10,500,000 
Elimination of Brooklyn’s historical members’ equity  -   (33,702,005)  (1,400,000)  (1,000,000)  (197,873)  -   -   36,299,878   -   - 
Common stock to be retained by NTN stockholders  -   -   -   -   -   
1,514,373
   7,572   8,170,042   -   8,177,614 
Issuance of Series A preferred stock retained by NTN stockholders  781   -   -   -   -   -   -   (781)  -   - 
Issuance of common stock to Brooklyn members  -   -   -   -   -   
38,923,957
   194,620   (194,620)  -   - 
Issuance of common stock to Financial Advisor upon consummation of merger  -   -   -   -   -   
1,067,668
   5,338   5,760,069   -   5,765,407 
Stock based compensation:                                      
 
Modification of vested restricted common shares  -   -   -   -   -   -   -   249,905   -   249,905 
Amortization
of restricted common shares
  -   -   -   -   -   -   -   168,996   -   168,996 
Net loss  -   -   -   -   -   -   -   -   (17,702,334)  (17,702,334)
Balance - March
31, 2021
 $781  $-  $-  $-  $-   41,505,998  $207,530  $50,453,489  $(55,083,075) $(4,421,275)

  Membership Equity  Accumulated  Total Members’ 


Class A

Class B 
Class C
 Common 
Deficit
 Equity
Balance - January 1, 2020 $18,177,692  $1,400,000  $1,000,000  $106,937  $(10,941,526) $9,743,103 
Stock based compensation:                        
Amortization of restricted common units  -   -   -   22,734   -   22,734 
Sale of members’ equity  312,500   -   -   -   -   312,500 
Net loss  -   -   -   -   (1,019,212)  (1,019,212)
Balance - March 31, 2020 $18,490,192  $1,400,000  $1,000,000  $129,671  $(11,960,738) $9,059,125 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

  Three Months Ended March 31, 
  2021  2020 
Cash Flows from Operating Activities:      
Net loss $(17,702,334) $(1,019,212)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization  25,287   22,999 
Modification of vested restricted common shares  249,905   - 
Equity compensation  168,996   22,734 
Amortization of right-to-use asset  69,615   - 
Transaction costs - shares to Financial Advisor  5,765,407   - 
Loss on sales of NTN assets  9,598,173   - 
Change in fair value of contingent consideration  (820,000)  - 
Change in operating assets and liabilities:        
Account receivable  4,680   - 
Prepaid expenses and other current assets  41,594   (53,459)
Security deposits and other non-current assets  (1,018)  (84,915)
Accounts payable and accrued expenses  (765,842)  (761,925)
Operating lease liability  (64,390)  - 
Other liabilities  -   685 
Total adjustments  14,272,407   (853,881)
Net Cash Used in Operating Activities  (3,429,927)  (1,873,093)
         
Cash Flows from Investing Activities:        
Purchase of property and equipment  -   (4,457)
Purchase of NTN, net of cash acquired  147,728   - 
Proceeds from the sales of NTN assets, net of cash disposed  118,594   - 
Net cash provided by / (used in) investing activities  266,322   (4,457)
         
Cash Flows from Financing Activities        
Repayment of NTN's PPP Loan  (531,994)  - 
Proceeds from sale of members' equity  10,475,082   312,500 
Net Cash Provided by Financing Activities  9,943,088   312,500 
         
Net Increase / (Decrease)  in Cash  6,779,483   (1,565,050)
Cash - Beginning of Period  1,630,455   5,100,819 
Cash - End of Period $8,409,938  $3,535,769 
         
Supplemental Disclosures of Cash Flow Information:        
Cash paid during the period for:        
Interest $-  $- 
Income taxes $-  $- 
         
Non-cash Investing and Financing Activities:        
Issuance of common stock for business combination $8,177,614  $- 
Repayment of aquired NTN debts upon disposition of assets to eGames $1,700,000  $- 
Preferred shares issued in connection with reverse merger $781  $- 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1ORGANIZATION AND DESCRIPTION OF BUSINESS OPERATIONS
Brooklyn ImmunoTherapeutics Inc. (“Brooklyn” or the “Company”), together with its subsidiary, Brooklyn ImmunoTherapeutics LLC (“Brooklyn LLC”) is a clinical stage biopharmaceutical company focused on developing a cytokine-based therapy to treat patients with cancer.
NTN Buzztime, Inc. Transaction

On August 12, 2020, the Company and NTN Buzztime, Inc. (“NTN”) and BIT Merger Sub, Inc. (the “Merger Sub”), a wholly owned subsidiary of NTN, entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). Pursuant to the Merger Agreement, among other matters, the Merger Sub merged with and into Brooklyn LLC, with Brooklyn LLC continuing as a wholly owned subsidiary of NTN and the surviving company of the merger. The merger was closed on March 25, 2021. After the merger, NTN changed its name to Brooklyn ImmunoTherapeutics, Inc. The merger was accounted for as a reverse acquisition with Brooklyn LLC being deemed the acquiring company for accounting purposes.

On March 26, 2021, the Company sold its rights, title and interest in and to the assets relating to the business it operated prior to the merger, which was operated under the name NTN Buzztime, Inc. to eGames.com Holdings LLC (“eGames.com”) in accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between NTN and eGames.com (the “Asset Purchase Agreement”) (See Note 4).
NOTE 2LIQUIDITY AND CAPITAL RESOURCES
The accompanying financial statements have been prepared assuming that it will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to develop product candidates, including conducting clinical trials and providing general and administrative support for these operations. As of March 31, 2021, the Company had a cash balance of $8,409,938 and an accumulated deficit of $55,083,075 (inclusive of a non-cash gain of $820,000 relating to change in fair value of contingent consideration and $9,598,173 relating to loss on sale of NTN assets). During the three months ended March 31, 2021, the Company incurred a net loss of $17,702,334 and used cash in operations of $3,429,927.
On April 26, 2021, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), which provides that the Company may offer to Lincoln Park up to an aggregate of $20,000,000 of the Company’s common shares over a 36-month period commencing after the date that a registration statement covering the resale of shares of common stock issued under the Purchase Agreement is declared effective by the Securities and Exchange Commission (the “SEC”). The registration statement was declared effective by the SEC on May 10, 2021 (the “Commencement Date”). As of May 14, 2021, we had issued and sold an aggregate of 302,358 shares of common stock to Lincoln Park pursuant to the Purchase Agreement, resulting in gross proceeds of $6.3 million.
The Company believes its existing cash resources and excess to additional cash under the Purchase Agreement are sufficient to fund its current operating plan for at least the next 12 months from the date financial statements were issued.
5

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 3BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
As described above, the merger with NTN closed on March 25, 2021. The merger was accounted for as a reverse acquisition with Brooklyn LLC being deemed the acquiring company for accounting purposes. Brooklyn LLC’s historical financial statements have replaced NTN’s historical financial statements with respect to periods prior to the completion of the merger. The Company retrospectively adjusted the weighted average shares used in determining loss per common share to reflect the conversion of the outstanding Class A units, Class B units, Class C units, and common units of Brooklyn LLC that converted into shares of the Company’s common stock upon the merger, and to reflect the effect of the 2 to 1 reverse stock split of the Company’s common stock which occurred upon the merger.
   The results for the unaudited condensed statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2021 or for any future interim period. The unaudited condensed financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (a) the reported amounts of assets and liabilities; (b) disclosure of contingent assets and liabilities at the date of the financial statements; (c) the reported amounts of revenues and expenses during the reporting period and (d) the reported amount of the fair value of assets acquired in connection with the business combination. Actual results could differ from those estimates. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the valuation of stock-based compensation and contingent consideration.
Paycheck Protection Program Loan
On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), as amended on June 5, 2020 by the Paycheck Protection Program (“PPP”). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carry back periods, and alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. On May 4, 2020, the Company was granted a loan (the “Loan”) from Silicon Valley Bank in the aggregate amount of $309,905, pursuant to the PPP under Division A, Title I of the CARES Act. The Company is continuing to evaluate and examine the impact the CARES Act may have on the business, results of operations, financial condition, or liquidity.
The Loan, which was in the form of a note dated May 4, 2020 issued by the Company, matures on May 4, 2022, and bears interest at a rate of 1% per annum.

6

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 3BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Paycheck Protection Program Loan (Continued)

In order to qualify for loan forgiveness, funds from the Loan may only be used for payroll costs, rent and utilities. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. The Company intends to comply with the loan forgiveness provisions in the legislation; however, there can be no assurance that the Company will obtain full forgiveness of the loans based on the legislation.
Cash and Cash Equivalents

The Company classifies highly liquid investments with a remaining contractual maturity at date of purchase of three months or less as cash equivalents. The Company had no cash equivalents as of March 31, 2021 and December 31, 2020.

Property and Equipment
Property and equipment are recorded at cost and are depreciated over their estimated useful lives using the straight-line method. Laboratory and manufacturing equipment are depreciated over an estimated useful life of 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful life, or the lease term. Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gain or losses are reflected in the results of operations. Expenditures for maintenance and repairs are charged to operations. Renewals and betterments are capitalized.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment annually, or if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying value. Since management evaluates the Company as a single reporting unit, goodwill is tested for impairment at the entity level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the entity is less than its carrying value. If the entity does not pass the qualitative assessment, then the entity’s carrying value is compared to its fair value. Goodwill is considered impaired if the carrying value of the entity exceeds its fair value.
In Process Research and Development
In-process research and development (“IPR&D”) assets represent the fair value assigned to technologies that were acquired on November 5, 2018 in connection with the Asset Purchase Agreement, which have not reached technological feasibility and have no alternative future use. IPR&D assets are considered to be indefinite lived until the completion or abandonment of the associated research and development projects. During the period that the IPR&D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives beginning at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value.
7

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 3BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Impairment of Long-Lived Assets
The Company reviews long-lived assets and certain identifiable assets for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recovered. An impairment exists when the carrying value of the long-lived asset is not recoverable and exceeds its fair value.
Research and Development
Research and development expenditures are charged to operations as incurred.
Income Taxes
The Company records deferred tax liabilities and assets based on the differences between the financial statements carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and established a valuation allowance when it was more likely than not that some portion or all of the deferred tax assets would not be realized. Income tax expense consists of the tax payable for the period and the change during the period in deferred tax assets and liabilities.
Tax benefits from uncertain tax positions are recognized only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company has no material uncertain tax positions for any of the reporting periods presented.
Concentration of Credit Risk
The Company maintains its cash balances in financial institutions located in the United States. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At times, the Company’s cash balances may be uninsured for deposit accounts that exceed the FDIC insurance limit.
A single vendor accounted for 29% of the Company’s purchases during the year ended March 31, 2021. A different vendor accounted for 23% of the Company’s purchases during the year ended December 31, 2020. In the Company’s business, vendor concentrations could be indicative of vulnerabilities in the Company’s supply chain, which could ultimately impact the Company’s ability to continue its research and development activities.
8

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 3BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:
Level 1 Inputs – Valued based on quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 Inputs – Valued based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.
Level 3 Inputs – Valued based on inputs for which there is little or no market value, which require the reporting entity to develop its own assumptions.
The carrying amounts reported on the balance sheet for prepaid assets and other current assets, accounts payable and accrued expenses, other current liabilities and other liabilities approximate fair value based due to their short maturities. The carrying value of loans payable approximates its fair market value because the effective yield on this debt, which includes contractual interest rates as well as other finance charges, is comparable to rates of returns for instruments of similar credit risk.
Leases
The Company accounts for its leases under the Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 842, Leases (“ASC842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the condensed consolidated balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term.
In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components as permitted under ASC 842.  The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.
9

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 3BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Commitment and Contingencies
The Company follows ASC No.450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
Equity Based Compensation
Compensation expense for equity-based awards granted to employees is based on the estimated grant-date fair value of the award and is recognized ratably over the vesting period.
Loss Per Share
Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.
For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily convertible preferred stock.
For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is antidilutive. Convertible preferred stock was excluded from the computations of diluted net loss per common share for the three months ended March 31, 2021, as its effect would be anti-dilutive.
Subsequent Events
The Company’s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.
Recent Accounting Standards and Pronouncements
Accounting Standards Recently Adopted
In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance sheet as a right-of-use asset and a lease liability. Leases will be classified as operating or financing. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard ASU 2016-02 is effective for fiscal years and interim periods, within those fiscal years, beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020, but early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements which allows entities to initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. ASU 2016-02 also requires expanded financial statement disclosures on leasing activities. These changes will become effective for the Company for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.  This ASU was adopted by the Company as of December 31, 2020 resulting in the Company recording ROU assets (as defined in Note 7 - Leases) and lease liabilities on the balance sheet.

10

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 3BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Accounting Pronouncements Recently Adopted

  In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intra-period allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on the Company’s condensed consolidated financial statements.
NOTE 4NTN BUZZTIME, INC TRANSACTION
Merger Agreement with NTN Buzztime, Inc.
On August 12, 2020, the Company, NTN and the Merger Sub, entered into the Merger Agreement. The merger closed on March 25, 2021. After the merger, NTN Buzztime, Inc. changed its name to Brooklyn ImmunoTherapeutics, Inc. The merger was accounted for as a reverse acquisition with Brooklyn LLC being deemed the acquiring company for accounting purposes. Brooklyn LLC, as the accounting acquirer, recorded the assets acquired and liabilities assumed of NTN in the merger at their fair values as of the acquisition date. The Company is trading on the NYSE American under the ticker symbol “BTX”.

11

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 4NTN BUZZTIME, INC TRANSACTION (Continued)

Merger Agreement with NTN Buzztime, Inc. (Continued)

Brooklyn LLC was determined to be the accounting acquirer based upon the terms of the merger and other factors including (i) Brooklyn LLC members and Maxim Group LLC, Brooklyn LLC’s financial advisor (the “Financial Advisor”) received 96.35% of NTN’s outstanding common stock on a fully diluted basis immediately following the effective time of the merger, (ii) all of the board of directors of combined company was composed of directors designated by Brooklyn LLC under the terms of the Merger Agreement and (iii) existing members of Brooklyn LLC’s management became the management of the combined company.
At the closing of the merger, all the outstanding membership interests of Brooklyn LLC’s converted into the right to receive shares of the Company’s common stock equal to the exchange ratio of 1-for-2. Brooklyn LLC exchanged all of their equity interests in Brooklyn LLC for an aggregate of 39,991,625 shares of common stock, of which 1,067,668 shares were issued as compensation to the Financial Advisor for its services to Brooklyn LLC in connection with the merger.
The purchase price, which represents the consideration transferred in the merger to NTN’s stockholders, is calculated based on the fair value of the common stock of the combined company that NTN’s stockholders owned as of the closing date of the merger because that represents a more reliable measure of the fair value of consideration transferred in the merger. Accordingly, the purchase price of $8,177,614, which was calculated as follows:

Number of shares of the Common Stock owned by NTN stockholders (i)  
1,514,373
 
Multiplied by the fair value per share of Common Stock (ii)  
5.40
 
Total purchase price 
$
8,177,614
 


(i)
The purchase price was determined based on the number of shares of common stock of the combined company that NTN’s stockholders owned immediately prior to the merger.

(ii)
The fair value per share is based on the closing price of $5.40 (post reverse stock split) per share of thecommon stock as reported on the NYSE American on March 25, 2021, the date of the merger.

Under the acquisition method of accounting, the total purchase price is allocated to the acquired tangible and intangible assets and assumed liabilities of NTN based on their estimated fair values as of the merger closing date. Because the consideration paid by Brooklyn LLC in the merger is more than the estimated fair values of NTN’s net assets acquired, goodwill equal to the difference has been reflected in the unaudited pro forma condensed consolidated balance sheet. The goodwill of $8,588,576 has been calculated using the fair values of the net assets of NTN as of March 25, 2021.

12

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 4NTN BUZZTIME, INC TRANSACTION (Continued)
Merger Agreement with NTN Buzztime, Inc. (Continued)
The preliminary allocation of the estimated purchase price to the tangible and intangible assets acquired and liabilities assumed from NTN, based on their estimated fair values as of March 25, 2021, is as follows:
  
Historical Balance Sheet
of NTN at March 25, 2020
  
Pro Forma Fair Value
Adjustment to NTN
Assets
  Preliminary Purchase
Price
Allocation Pro Forma
Adjustment
 
Cash and cash equivalents 
$
147,728
  
$
-
  
$
147,728
 
Accounts receivable  
102,517
   
-
   
102,517
 
Prepaid expense and other current assets  
329,596
   
-
   
329,596
 
Property and equipment, net  
1,015,370
   
-
   
1,015,370
 
Software development costs  
1,296,460
   (368,460)  
928,000
 
Customers  
-
   
548,000
   
548,000
 
Trade name  
-
   
299,000
   
299,000
 
Accounts payable, accrued liabilities and other current liabilities  (3,781,173)  
-
   (3,781,173)
Net assets acquired, excluding goodwill 
$
(889,502
)
 
$
478,540
  
$
(410,962
)
             
Total consideration 
$
8,177,614
         
Net assets acquired, excluding goodwill  (410,962)        
Goodwill 
$
8,588,576
         
13

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 4NTN BUZZTIME, INC TRANSACTION (Continued)
Disposition

On March 26, 2021, the Company sold its rights, title and interest in and to the assets relating to the business operated by NTN prior to the merger to eGames.com in exchange for a payment of a purchase price of $2,000,000 and assumption of specified liabilities relating to the NTN business. The sale was completed in accordance with the terms of the Asset Purchase Agreement.

In the Disposition, the Company sold specified NTN assets and liabilities acquired as a result of the reverse acquisition to eGames.com, an unrelated party, for cash consideration of $2,000,000. Details of the Disposition are as follows:

Proceeds from sale:   
Cash $132,055 
Escrow  100,000 
Assume advance/loans  1,700,000 
Interest on advance/loans  67,945 
     
Carrying value of assets sold:    
Cash and cash equivalents  (13,461)
Accounts receivable  (75,153)
Prepaids and other current assets  (123,769)
Property and equipment, net  (1,013,950)
Software development costs  (927,368)
Customers  (548,000)
Trade name  (299,000)
Goodwill  (8,588,576)
Other assets  (103,173)
     
Liabilities transferred upon sale:    
Accounts payable and accrued expenses  113,156 
Obligations under finance leases  16,676 
Lease liability  25,655 
Deferred revenue  54,803 
Other current liabilities  148,987 
     
Transaction costs  (265,000)
     
Total loss on sale of assets $(9,598,173)

14

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 4NTN BUZZTIME, INC TRANSACTION (Continued)
Rights Offering
The Company was obligated under the Merger Agreement to have $10,000,000 in cash and cash equivalents on its balance sheet at the effective time of the merger (the “Required Funds”). To ensure that the Company has the Required Funds, certain beneficial holders of Brooklyn LLC’s Class A membership interests have entered into contractual commitments to invest $10,000,000 into Brooklyn LLC immediately prior to the closing of the merger with NTN. During March 2021 the Company offered to its Class A unit holders an additional 5% rights offering, a total amount of $500,000 was raised by this right offering. Funding to the rights offering was received between February 17 and April 5, 2021.
Unaudited Pro Forma Disclosure
The following unaudited pro forma financial information summarizes the results of operations for the three months ended March 31, 2021 and 2020 as if the merger and disposal described above had been completed as of January 1, 2020. Pro forma information primarily reflects adjustments relating to the reversal of transaction costs. Assuming that the merger had been completed as of January 1, 2020, the transaction costs would have been expensed in the prior period.
  Three Months Ended March 31, 
  2021  2020 
        
Net loss attributable to common stockholders $(17,702,334) $(1,019,212)
         
Basic and diluted net loss per share attributable to common stockholders $(0.64) $(0.06)
NOTE 5FAIR VALUE OF FINANCIAL INSTRUMENTS
Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:
Level 1 Inputs – Valued based on quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 Inputs – Valued based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.
15

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 5FAIR VALUE OF FINANCIAL INSTRUMENTS (Continued)
Level 3 Inputs – Valued based on inputs for which there is little or no market value, which require the reporting entity to develop its own assumptions.
The following tables summarize the liabilities that are measured at fair value as of March 31, 2021 and December 31, 2020:
  March 31, 2021 
Description Level 1  Level 2  Level 3 
Liabilities:         
Contigent consideration  -   -   19,290,000 
Total $-  $-  $19,290,000 

  December 31, 2020 
Description Level 1  Level 2  Level 3 
Liabilities:         
Contigent consideration  -   -   20,110,000 
Total $-  $-  $20,110,000 
Contingent consideration has initially been valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party valuation services or other market observable data. The third-party valuation services utilize industry standard valuation models, including discounted cash flow analysis to determine value. After completing its validation procedures, the Company adjusted the fair value carrying amount as of March 31, 2021. The contingent consideration is resultant to the Asset Purchase Agreement with IRX entered by the Company for the acquisition of substantially all of the net assets of IRX, according to which, Brooklyn is obligated to pay royalties to certain noteholders and shareholders of IRX based on future revenues from any future IRX-2 product sales. The fair value of the contingent consideration has been estimated using the discounted cash flow method of the income approach.
The following table reflects the activity for the Company’s contingent consideration liabilities measured at fair value using Level 3 inputs for the year ended March 31, 2021:
  
Other Liabilities:
Contingent
Consideration
 
Balance at December 31, 2020 $20,110,000 
Fair value adjustments included in operating expenses  (820,000)
Balance at March 31, 2021 $19,290,000 
Contingent consideration is measured at fair value and is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions the Company believes would be made by a market participant. The Company assesses these estimates on an on-going basis as additional data impacting the assumptions is obtained. Future changes in the fair value of contingent consideration related to updated assumptions and estimates are recognized within the statements of operations.
16

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 5FAIR VALUE OF FINANCIAL INSTRUMENTS (Continued)

Contingent consideration may change significantly as development progresses and additional data are obtained, impacting the Company’s assumptions regarding probabilities of successful achievement of related milestone used to estimate the fair value of the liability and the timing in which they are expected to be achieved. In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange.

Accordingly, the use of different market assumptions and/or different valuation techniques could result in materially different fair value estimates.
For purposes of this calculation, a royalty equal to 13% of revenue (consisting of the royalty due to University of South Florida and the royalty due to the collaborator) is assumed until 2029 and a royalty of 7% of revenues is assumed from 2030 to 2038. The post patent decline is 50% in the first year and 10% thereafter. Income taxes were projected to be 26% of net Company royalty savings. The cash flows were discounted by the liability specific weighted average cost of capital of 24% using the mid-point convention.
NOTE 6
20PROPERTY AND EQUIPMENT
Property and equipment consist of the following:
  March 31,  December 31, 
  2021  2020 
 Laboratory and manufacturing equipment $299,839  $299,839 
 Leasehold improvements  414,504   414,504 
   714,343   714,343 
 Less: accumulated depreciation and amortization  (145,400)  (120,237)
 Property and equipment, net $568,943  $594,106 
Depreciation expense charged to operations during the three months ended March 31, 2021 was $25,163. Depreciation expense charged to operations was $22,999 during the three months ended March 31, 2020.
NOTE 7LEASES
The Company adopted ASC 842, Leases on December 31, 2020 using the modified transition method without retrospective application to comparative periods. The Company elected the package of three practical expedients allowed for under the transition guidance. Accordingly, the Company did not reassess: (1) whether any expired or existing contracts are/or contain leases; (2) the lease classification for any expired or existing leases; or (3) initial direct costs for any existing leases. The Company has also elected not to recognize right of use assets (“ROU assets”) and lease liabilities for short-term leases that have a term of 12 months or less.
17

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 7LEASES (Continued)
The Company’s material operating leases consist of corporate office, as well as laboratory space. The office space is situated at 654 Madison Ave in New York, NY and expires on November 30, 2026. The laboratory space situated in Brooklyn, New York.  Effective on July 1, 2019, the laboratory lease was amended to increase the space rented under the laboratory lease, rent increases 3% on January 1 of each lease year. The laboratory lease expires on December 31, 2025. The leases have remaining terms of 5 - 6 years. Brooklyn determines if an arrangement meets the criteria of a lease at inception, at which time it also performs an analysis to determine whether the lease qualifies as operating or financing. The Company does not currently have any finance leases.
Operating lease liabilities represent the present value of lease payments not yet paid. ROU assets represent Brooklyn’s right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepaid or accrued lease payments, initial direct costs, lease incentives and impairment of operating lease assets. As the rate implicit in the lease is not readily determinable, the Company used its incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. To determine the present value of lease payments not yet paid, the Company estimates secured borrowing rates corresponding to the maturities of the leases.
The Company has elected the practical expedient to not separate non-lease components from the lease components to which they relate and instead account for each as a single lease component, for all underlying asset classes. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance, tax payments and other miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.
Operating leases are included in right of use assets - operating leases and operating lease liabilities, current and long-term, in the balance sheet. Lease expense for operating leases is recognized on a straight-line basis over the lease term and is included in selling, administrative and other operating costs in the statements of operations.
In accordance with provisions of ASC 842 Leases (“ASC 842”), we treated the sublease as a separate lease as we were not relieved of the primary obligation under the original lease. The Company continue to account for the original Manhattan facility, as a lessee, in the same manner as prior to the commencement date of the sublease. The Company accounted for the sublease as a lessor of the lease. The sublease is classified as an operating lease as it did not meet the criteria of a Sale-Type or Direct Financing lease.
18

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 7LEASES (Continued)
The Company recognize operating lease expense and lease payments from the sublease, on a straight-line basis, in its statements of operations over the lease terms. During the three months ended March 31, 2021, the net operating lease expenses are as follows:
  
Three Months Ended
March 31, 2021
 
Operating lease expense 
$
150,865
 
Sublease income  
(21,045
)
Variable lease expense  9,002 
Total $138,822 
The table below provides supplemental information related to operating leases for the three months ended:
  Three Months Ended
March 31, 2021
 
Cash paid within operating cash flow $154,641 
Weighted average remaining lease term (years)  5.25 
Weighted average discount rate  14.5%
Maturities of operating lease liabilities as of March 31, 2021:

For the Three Months Ending
March 31,
 Amount 
Remaining of  2021 $428,878 
2022  588,918 
2023  606,864 
2024  624,172 
2025  641,981 
Thereafter  105,674 
Future lease payments  2,996,487 
Less: Imputed interest $882,265 
Total operating lease liabilities  2,114,222 

19

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 7LEASES (Continued)
Sublease Agreement
On April 18, 2019, the Company entered into a sublease agreement with Nezu Asia Capital Management, LLC (“the Tenant”), whereby the Tenant agreed to sublease approximately 999 square feet of space currently rented by the Company in New York, NY, for an initial term of 8 years, commencing on May 15, 2019.  The term of the sublease expires on October 31, 2026 with no option to extend the sublease term.  Rent payments provided by the Tenant under the sublease agreement began on September 1, 2019. The sublease agreement stipulates an annual rent increase of 2.25%. The Tenant also is responsible for paying to the Company all tenant energy costs, annual operating costs, and annual tax costs attributable to the subleased space during the term of the sublease.
Future lease payments as of March 31, 2021 from the sublease agreement are as follows:
For the Three Months Ending
March 31,
  Amount  
Remaining of  2021 $60,655 
2022  82,419 
2023  84,194 
2024  86,010 
2025  87,867 
Thereafter  74,590 
Total $475,735 
The Company received sublease payments $20,027 during the three months ended March 31, 2020.
NOTE 8GOODWILL AND IN PROCESS RESEARCH AND DEVELOPMENT
The Company recorded Goodwill and IPR&D in the amount of $2,043,747 and $6,860,000, respectively, in connection with the acquisition of IRX. IPR&D assets are considered to be indefinite lived until the completion or abandonment of the associated research and development projects.
NOTE 9SECURITY DEPOSITS AND OTHER ASSETS
On January 24, 2020, the Company replaced the letter of credit held for lease property 654 Madison Avenue with a security deposit of $84,915.
On February 9, 2017, a retainer in the amount of $300,401 to a service provider was paid, pursuant to a master services agreement (the “Master Services Agreement”) which expires in 2022. The retainer represented 10% of the amount of estimated direct costs expected to be incurred by the service provider, in connection with clinical development services provided under the Master Services Agreement.
20

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 9
SECURITY DEPOSITS AND OTHER ASSETS (Continued)

On June 14, 2018, a security deposit was paid in the amount of $63,220 pursuant to a lease agreement which expires on December 28, 2025.
NOTE 10
ACCRUED EXPENSES
Accrued expenses consist of the following:
  March 31,  December 31, 
  2021  2020 
Compensation payable $588,266  $293,534 
Accrued general and administrative expenses  57,702   207,468 
Accrued research and development expenses  349,592   399,893 
Accrued interest  164,784   150,125 
Total accrued expenses $1,160,344  $1,051,020 
NOTE 11LOANS PAYABLE
In connection with the acquisition of IRX the Company assumed certain notes payable (“IRX Notes”) in the amount of $410,000. On January 27, 2020, the IRX Notes were amended to extend the maturity date to the earlier of (i) a change of control, as defined, or (ii) December 31, 2021.
NOTE 12COMMITMENTS AND CONTINGENCIES
Legal Matters
The Company is involved in litigation and arbitrations from time to time in the ordinary course of business. Legal fees and other costs associated with such actions are expensed as incurred. In addition, the Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and contingencies. The Company reserves for costs relating to these matters when a loss is probable, and the amount can be reasonably estimated.
University of South Florida
As of December 31, 2019, the Company was involved in a legal matter with the University of South Florida (“USF”), whereby USF sent a demand letter to IRX and Brooklyn LLC on December 21, 2018, contending its right to 25% of IRX proceeds from the business combination. The Company entered into a settlement agreement with USF on August 7, 2020. The amount of $150,000 was paid on August 19, 2020. Other than the royalty payments described below, no other amounts are due to USF under the license agreement.
21


INTRODUCTIONTable of Contents

BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 12COMMITMENTS AND CONTINGENCIES (Continued)
Legal Matters (Continued)

Litigation

Transaction between NTN and Brooklyn LLC / Related NTN Shareholder Litigation

NTN and its former directors have been named as defendants in ten (10) substantially similar actions brought by purported stockholders of NTN arising out of the merger: Henson v. NTN Buzztime, Inc., et al., No. 1:20-cv-08663-LGS (S.D.N.Y.); Monsour v. NTN Buzztime, Inc., et al., No. 1:20-cv-08755-LGS (S.D.N.Y.); Amanfo v. NTN Buzztime, Inc., et al., No. 1:20-cv-08747-LGS (S.D.N.Y.); Carlson v. NTN Buzztime, Inc., et al., No. 1:21-cv-00047-LGS (S.D.N.Y.); Finger v. NTN Buzztime, Inc., et al., No. 1:21-cv-00728-LGS (S.D.N.Y.); Falikman v. NTN Buzztime, Inc., et al., No. 1:20-cv-05106-EK-SJB (E.D.N.Y.); Haas v. NTN Buzztime, Inc., et al., No. 3:20-cv-02123-BAS-JLB (S.D. Cal.); Gallo v. NTN Buzztime, Inc., et al., No. 3:21-cv-00157-WQH-AGS (S.D. Cal.); Chinta v. NTN Buzztime, Inc., et al., No. 1:20-cv-01401-CFC (D. Del.); and Nicosia v. NTN Buzztime, Inc., et al., No. 1:21-cv-00125-CFC (D. Del.) (collectively, the “Stockholder Actions”).  Only two of these suits (the Chinta and Nicosia cases) also name the Company.  These actions assert claims alleging violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and Securities Exchange Commission Rule 14a-9 promulgated thereunder and in both the Chinta and Nicosia cases alleged that the Company is a controlling person of NTN.  The complaints generally allege that the defendants failed to disclose allegedly material information in a Form S-4 Registration Statement filed on October 2, 2020, including:  (1) certain details regarding any projections or forecasts of NTN or the Company may have made, and the analyses performed by NTN’s financial advisor, Newbridge Securities Corporation; (2) conflicts concerning the sales process; and (3) disclosures regarding whether or not NTN entered into any confidentiality agreements with standstill and/or “don’t ask, don’t waive” provisions.  The complaints generally allege that these purported failures to disclose rendered the Form S-4 false and misleading.  The complaints request preliminary and permanent injunction of the merger; rescission of the merger if executed and/or rescissory damages in unspecified amounts; direction to the individual directors to disseminate a compliant Registration Statement; an accounting by NTN for all alleged damages suffered; a declaration that certain federal securities laws have been violated; and costs, including attorneys’ and expert fees and expenses.  On or about February 26, 2021, in order to moot certain of the disclosure claims asserted in the Stockholder Actions, to avoid nuisance, potential expense, and delay, and to provide additional information to NTN’s stockholders, NTN  determined to voluntarily supplement the Proxy Statement with certain additional disclosures.  In exchange for those disclosures the Plaintiffs in each of the ten actions agreed to voluntarily dismiss their claims.  All ten actions have now been dismissed.  The parties are presently attempting to resolve plaintiffs’ counsel’s request for an award of attorneys’ fee and expenses based on the purported benefit they contend was conferred on NTN’s stockholders as a result of the supplemental disclosures.  If agreement cannot be reached, plaintiffs’ counsel have reserved their right to seek a fee and defendants have reserved their right to challenge fee application.

Dhesh Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021)

On or about February 5, 2021, Dhesh Govender, a former short-term consultant of the Company, filed a complaint against the Company and certain individuals that plaintiff alleges are directors of the Company.  The complaint is captioned, Dhesh Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021).  Plaintiff purports to state claims against the Company and the individual defendants under the New York State Executive Law, New York State Administrative Code and other statutory and common law claims for alleged unlawful and discriminatory conduct based on race, national origin and hostile work environment.  Plaintiff also asserts various breach of contract, fraud and quantum meruit claims based on an alleged oral agreement pursuant to which he alleges the Company agreed to hire him as an executive once the Company went public. In particular, plaintiff alleges that in exchange for transferring an opportunity to obtain an agreement to acquire a license from Novellus for its mRNA-based gene editing and cell reprogramming technology (the “Novellus License”) to the Company, he was promised a $500,000 salary and 7% of the equity of the Company.  Based on these and other allegations, plaintiff seeks damages of not less than $10 million, a permanent injunction enjoining the Company from exercising the option to acquire the Novellus License or completing the proposed merger with NTN.  On or about February 19, 2021, an amended complaint was filed asserting the same causes of action but withdrawing the request for injunctive relief.  On or about April 26, 2021, the parties entered into a stipulation whereby the defendants agreed to accept service of the Amended Complaint without waiver of any defenses, including jurisdictional defenses, except for improper service, and the plaintiff agreed to extend Defendants time to respond to the Complaint to June 6, 2021.

22

BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 12COMMITMENTS AND CONTINGENCIES (Continued)

Legal Matters (Continued)

Litigation (Continued)

Carlson v. Allen Wolff, Michael Gottlieb, Richard Simtob, Susan Miller, and NTN Buzztime, Inc., C.A. No. 2021-0193-KSJM (Del. Ch. Ct.)

On or about March 12, 2021, Douglas Carlson, a purported stockholder of NTN Buzztime, Inc., filed a verified class action complaint against NTN and its then current members of the board of directors, for allegedly breaching their fiduciary duties and violating Section 211(c) of the Delaware General Corporation Law.  In particular, plaintiff seeks to compel the defendants to hold an annual stockholder meeting.  Plaintiff also moved for summary judgment at the same time that he filed his complaint.  In order to moot the claim addressed in the complaint, the Company has agreed to hold its annual meeting on June 29, 2021.  On or about May 6, 2021, the parties entered into a stipulation, which was “so ordered” by the Court, extending defendants time to respond to the complaint and file their answering brief in opposition to Plaintiff’s motion for summary judgment on or before July 16, 2021 and Plaintiff’s reply brief in support of his motion for summary judgment is due on or before August 20, 2021.

Robert Garfield Demand Letter

On April 29, 2021, Robert Garfield, a purported stockholder of the Company forwarded a demand letter (the “Demand”) that had purportedly been sent to NTN Buzztime, Inc. on or about March 16, 2021, to the Company asserting that  NTN Buzztime, Inc.  made material misstatements in a prospectus issued in connection with it seeking a stockholder vote on March 15, 2021 with respect to an amendment to the Company’s certificate of incorporation to increase the company’s authorized shares from 15M to 100M shares.  The Demand seeks to have the Company deem the amendment ineffective or seek a valid stockholder approval of such amendment to the Certificate of Incorporation and for the Company to implement internal controls.

Edmund Truell Matter

On May 14, 2021, Edmund Truell, a shareholder alleged that he sustained loss because he was unable to sell shares timely due to the Company’s delayed issuance of paper stock certificates in lieu of electronic book entry.

Licensing Agreements
University of South Florida
The Company has license agreements with USF, granting the Company the right to sell, market, and distribute IRX-2, subject to a 7% royalty payable to USF based on a percentage of gross product sales. Under the license agreement with USF, the Company is obligated to repay patent prosecution expenses incurred by USF. To date, the Company has not recorded any product sales, or obligations related to USF patent prosecution expenses. The license agreement terminates upon the expiration of the IRX-2 patents.
Novellus
In December 2020 (and as amended in April 2021), the Company entered into option agreements with Novellus Therapeutics Limited and Factor Bioscience Limited (together, Novellus) to obtain the right to exclusively license Novellus’ IP and mRNA cell reprogramming and gene editing technology for use in the development of certain cell-based therapies to treat cancer and rare blood disorders, such as sickle cell disease and beta thalassemia.
The option is exercisable before May 21, 2021 and requires Brooklyn to pay a non-refundable option fee of $500,000 (even if the option is not exercised). Brooklyn paid an advance on the license fees owed of $1 million on April 13, 2021, for an extension of the option until May 21, 2021.

23

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 12COMMITMENTS AND CONTINGENCIES (Continued)
Licensing Agreements (Continued)
Novellus (Continued)
The license agreement is currently being negotiated which include the following material terms:
Brooklyn will pay an upfront payment of $4,000,000 (inclusive of the $500,000 option fee) and receive an exclusive license (with right to sublicense) to Novellus’ patents, including know-how and any improvements, for developing and commercializing certain cell-based therapies. As discussed above Brooklyn already paid an advance of $1,000,000 of the license fee on April 13, 2021 and $1,500,000 on April 29, 2021.
Upon payment of additional milestones of $5,000,000 (within 6 months of signing) and $7,000,000 (within 18 months of signing), Brooklyn will have the ability to acquire additional cell lines for developing cell-based therapies in cancer and rare blood disorders.
Royalty Agreements
Collaborator Royalty Agreement
Effective June 22, 2018, IRX terminated its Research, Development and Option Facilitation Agreement and its Options Agreement (the “RDO and Options Agreements”) with a collaborative partner (the “Collaborator”), pursuant to a termination agreement (the “Termination Agreement”). In connection with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Options Agreements were terminated, and the IRX has no obligation to refund any payments received from the Collaborator. As consideration for entering into the Termination Agreement, the Collaborator will receive a royalty equal to 6% of revenues from the sale of IRX-2, for the period of time beginning with the first sale of IRX-2 through the later of (i) the twelfth anniversary of the first sale of IRX-2, or (ii) the expiration of the last IRX patent, or other exclusivity of IRX-2.
Investor Royalty Agreement
On March 22, 2021, Brooklyn restated its royalty agreement with the former Class A membership investors of the GP and LP (the “Investor Royalty Agreement”), whereby such beneficial holders will continue to receive royalties in an aggregate amount equal to 4% of the net revenues of the Company.
Royalty Agreement with certain former IRX Therapeutics investors
On May 1, 2012, IRX Therapeutics entered into a royalty agreement, which we refer as the IRX Investor Royalty Agreement, with certain investors who participated in a financing transaction. The IRX Investor Royalty Agreement was assigned to Brooklyn LLC in November 2018 when Brooklyn LLC acquired the assets of IRX Therapeutics. Pursuant to the IRX Investor Royalty Agreement, when Brooklyn LLC becomes obligated to pay royalties to the Research Association under the USF License Agreement, it will pay an additional royalty of 1% of gross sales to an entity organized by the investors who participated in such financing transaction. There are no termination provisions in the IRX Investor Royalty Agreement. The Company has not recognized any revenues to date, and no royalties are due pursuant to the any of the above-mentioned royalty agreements.
24

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 12COMMITMENTS AND CONTINGENCIES (Continued)
Employment Agreements
On July 8, 2020, the Brooklyn entered into a retention agreement (the “Retention Agreement”) with an employee (the “Employee”).  Pursuant to the Retention Agreement, the Employee was paid a lump sum of $200,000 in the second quarter of 2021.
In addition, the Company may unilaterally elect a second retention period from January 8, 2021 to July 8, 2021 (the “Second Retention Period”). The Company has elected not to make the Second Retention Period payment.
NOTE 13STOCK-BASED COMPENSATION
Pursuant to the merger Brooklyn LLC’s restricted common units 3,427 were replaced with 629,643 restricted common shares. There were no changes to any conditions and requirements to the restricted common shares. The shares vest quarterly till December 31, 2022. Due to the modification of the restricted common units, the fair value immediately after the merger was compared to the fair value of the restricted common units immediately prior to the merger. An expense to the value of $249,905 was recognized in the statement of operations for the three months ended March 31, 2021, which relates to prior periods vesting of restricted common shares.
The Company measures restricted employee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award.
During the three months ended March 31, 2021, 31,296 restricted common shares were vested. As of  March 31, 2021, there were 219,069 unvested restricted common stock issued by the Company.
The stock-based compensation expense for three months end March 31, 2021 and 2020 (including prior period vesting expense) was $418,901 and $22,734, respectively. As of March 31, 2021, there was $1,182,970 of unrecognized stock-based compensation expense related to non-vested restricted common shares.
NOTE 14STOCKHOLDERS’ DEFICIT
On March 25, 2021, immediately prior to the merger, the Company filed an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split. As a result of the reverse stock split, the number of issued and outstanding shares of common stock immediately prior to the reverse stock split was reduced into a smaller number of shares, such that every two shares of common stock held by a stockholder of the Company immediately prior to the reverse stock split were combined and reclassified into one share of common stock after the reverse stock split.
Immediately following the reverse stock split there were approximately 1,514,373 shares of common stock outstanding prior to the merger. No fractional shares were issued in connection with the reverse stock split.
Under the terms of the Merger Agreement, the Company issued shares of common stock to the holders of common units. The 86,667 Class A units have been converted into 22,274,718 shares of common stock, the 15,000,000 Class B units have been converted into 2,514,714 shares of common stock, the 10,000,000 Class C units have been converted in to 1,676,308, common units have been converted to 629,643 shares of common stock, and 10,500,000 rights options have been converted to 11,828,575.
25

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 14
STOCKHOLDERS’ DEFICIT (Continued)
On March 25, 2021, pursuant to the Merger Agreement (see Note 1), 1,514,373 shares of common stock were issued for the acquisition of NTN (see Note 4), with a fair value of approximately $8,177,614 or $5.40 per share.
On March 25, 2021, pursuant to the Merger Agreement, 1,067,879 shares of common stock were issued to the Company’s financial advisors (See Note 1).
NOTE 15SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date financial statements were issued. Other than as described herein, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements.
From time to time, the Company is subject to legal proceedings in the ordinary course of business. While management presently believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm its financial position, cash flows, or overall trends in results of operations, legal proceedings are subject to inherent uncertainties, and unfavorable rulings or outcomes could occur that have, individually or in the aggregate, a material adverse effect on the Company’s business, financial condition, or operating results. The Company is not currently subject to any pending material legal proceedings except as described below.
Private Placement Offerings
On April 26, 2021, the Company and Lincoln Park executed a (i) a purchase agreement (the “Purchase Agreement”); and (ii) a registration rights agreement (the “Registration Rights Agreement”). Pursuant to the Purchase Agreement, the Company will have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park will be obligated to purchase up to $20,000,000 in the aggregate of shares of common stock. Sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company’s sole discretion. For entering into the Purchase Agreement, the Company issued to Lincoln Park 56,041 shares of common shares as consideration for Lincoln Park’s commitment to purchase up to $20,000,000 shares of common stock.  
Following the Commencement Date, under the Purchase Agreement, on any business day selected by the Company, the Company may direct Lincoln Park to purchase up to 60,000 shares of common stock on such business day (each, a “Regular Purchase”), provided, however, that (i) the Regular Purchase may be increased to up to 80,000 shares, provided that the closing sale price of the common stock is not below $5.50 on the purchase date; and (ii) the Regular Purchase may be increased to up to 120,000 shares, provided that the closing sale price of the common stock is not below $7.00 on the purchase date. In each case, Lincoln Park’s maximum commitment in any single Regular Purchase may not exceed $1,000,000. The purchase price per share for each such Regular Purchase will be based off of prevailing market prices of common stock immediately preceding the time of sale. In addition to Regular Purchases, the Company may direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases if the closing sale price of the common stock exceeds certain threshold prices as set forth in the Purchase Agreement.
The Purchase Agreement also prohibits the Company from directing Lincoln Park to purchase any shares of common stock if those shares, when aggregated with all other shares of common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 4.99% of the then total outstanding shares of common stock.
26

Table of Contents
BROOKLYN IMMUNOTHERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 15SUBSEQUENT EVENTS (Continued)
Private Placement Offerings (Continued)
The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty.
Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The Company expects that any net proceeds received by the Company from such sales to Lincoln Park will be used for research and development, working capital and general corporate purposes.
As of May 14, 2021, we had issued and sold an aggregate of 302,358 shares of common stock to Lincoln Park pursuant to the Purchase Agreement, resulting in gross proceeds of $6.3 million.
Issuance of Option Grants
Howard J. Federoff, M.D., Ph.D., was appointed as Chief Executive Officer, President and a director of the Company as of April 16, 2021. Upon the appointment of Dr. Federoff, he was granted a nonqualified stock option covering 2,627,915 shares of Brooklyn’s common stock (the “Time-Based Option”).
The Time-Based Option will have a per share exercise price equal to the closing price of a share of Brooklyn’s common stock on the NYSE American Stock Exchange on 16 April 2021. Of the shares covered by the Time-Based Option, 656,979 will vest on April 16, 2022, 54,748 will vest on the sixteenth day of each month from May 2022 through March 2025, and the remaining 54,756 will vest on April 16, 2025, in each case for so long as the Dr. Federoff provides continuous service to Brooklyn through the relevant vesting date.
Additionally, on 16 April 2021, Dr. Federoff was granted a nonqualified stock option covering 597,253 shares of Brooklyn’s common stock (the “Milestone Option”). The Milestone Option will have a per share exercise price equal to the closing price of a share of Brooklyn’s common stock on the NYSE American Stock Exchange on 16 April 2021. The Milestone Option will fully vest upon the first concurrence by the US Food and Drug Administration that a proposed investigation may proceed following review of a BTX filed investigational new drug application in connection with that certain license among Brooklyn, Factor Biosciences Therapeutics Limited and Novellus Therapeutics Limited. This milestone is subject to Dr. Federoff’s continuous service with Brooklyn through such vesting date.
The unvested portion of the Time-Based Option and the Milestone Option will terminate upon the termination of Dr. Federoff’s employment with Brooklyn for any reason, subject to certain vesting acceleration provisions upon a qualifying termination, as described in his employment agreement with Brooklyn. Unless earlier terminated in accordance with their terms, each of the Time-Based Option and the Milestone Option will otherwise expire on the 10th anniversary of their respective grant date and be subject to the terms and conditions of the respective option agreement approved by Brooklyn. Each of the Time-Based Option and the Milestone Option is intended to constitute an “employment inducement grant” in accordance with the employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide, and is offered as an inducement material to Dr. Federoff in connection with Brooklyn’s hiring of Dr. Federoff and will be granted outside of Brooklyn’s shareholder-approved equity compensation plans.
28

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Management’s discussion and analysis of financial condition and results of operations is provided as a supplement to, and should be read with, the accompanying unaudited condensed consolidated financial statements and notes, included in Item 1 of Part I of this Quarterly Report on Form 10-Q,report, to help provide an understanding of our financial condition, the changes in our financial condition and our results of operations. All dollar amounts
Background
On March 25, 2021, BIT Merger Sub, Inc., a wholly owned subsidiary of Brooklyn Inc. (then known as NTN Buzztime, Inc.) merged with and into Brooklyn LLC, with Brooklyn LLC surviving as a wholly owned subsidiary of Brooklyn Inc.. This transaction, which we refer to as the Merger, was completed in this discussion are roundedaccordance with the terms of an agreement and plan of merger and reorganization dated August 12, 2020 among Brooklyn Inc. (then known as NTN Buzztime, Inc.), BIT Merger Sub, Inc. and Brooklyn LLC. In accordance with such agreement and plan of merger, on March 25, 2021 Brooklyn Inc. amended its restated certificate of incorporation in order to effect:
prior to the nearest thousand. Our discussion is organized as follows:

Overview and Highlights.  This section describes our business and significant events and transactions we believe are important in understanding our financial condition and results of operations.
Critical Accounting Policies.  This section lists our significant accounting policies, including any material changes in our critical accounting policies, estimates and judgments during the three months ended March 31, 2020 from those described in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our 2019 10-K.
Results of Operations.  This section provides an analysis of our results of operations presented in the accompanying unaudited condensed consolidated statements of operations by comparing the results for the three months ended March 31, 2020 to the results for the three months ended March 31, 2019.
Liquidity and Capital Resources.  This section provides an analysis of our historical cash flows, and our future capital requirements.
Recent Accounting Pronouncements. This section provides information related to new or updated accounting guidance that may impact our consolidated financial statements.
Off-Balance Sheet Arrangements. This section provides information related to any off-balance sheet arrangement we may have that would affect our consolidated finance statements.

OVERVIEW AND HIGHLIGHTS

About Our Business and How We Talk About It

We deliver interactive entertainment and innovative technology to our partners inMerger, a wide rangereverse stock split of verticals – from bars and restaurants to casinos and senior living centers. By enhancing the overall guest experience, we believe we help our hospitality partners acquire, engage, and retain patrons.

Through social fun and friendly competition, our platform creates bonds between our hospitality partners and their patrons, and between patrons themselves. We believe this unique experience increases dwell time, revenue, and repeat business for venues – and has also createdits common stock, par value $0.005 per share, at a large and engaged audienceratio of one-for-two, which we connect with through our in-venue TV network. Untilrefer to as the significant disruptionsReverse Split; and

following the Merger, a change in its corporate name from “NTN Buzztime, Inc.” to “Brooklyn ImmunoTherapeutics, Inc.”
On March 26, 2021, Brooklyn Inc. sold its rights, title and interest in and to the restaurantassets relating to the business it operated prior to the Merger, which it had operated under the name “NTN Buzztime, Inc.,” to eGames.com Holdings LLC, or eGames.com, in exchange for eGames.com’s payment of a purchase price of $2.0 million and bar industry resultingassumption of specified liabilities relating to such pre-Merger business. This transaction, which we refer to as the Asset Sale, was completed in accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between Brooklyn Inc. and eGames.com.
Following the completion of the Merger and the Asset Sale, our business consists exclusively of the business conducted by Brooklyn LLC.
The Merger has been accounted for as a reverse acquisition in accordance with United States generally accepted accounting principles, or GAAP. Under this method of accounting, Brooklyn LLC was deemed the “acquiring” company and Brooklyn Inc. (then known as NTN Buzztime, Inc.) was treated as the “acquired” company for financial reporting purposes. Operations prior to the Merger are those of Brooklyn LLC, and the historical financial statements of Brooklyn LLC became the historical financial statements of Brooklyn Inc. with respect to periods prior to the completion of the Merger. The weighted average shares used in determining loss per common share were retrospectively adjusted to reflect the conversion of the outstanding Class A, Class B, Class C and common units of Brooklyn LLC that converted into shares of Brooklyn Inc.’s common stock upon the Merger, and all share and per share amounts of common stock have been retrospectively restated to reflect the Reverse Split.
Overview
We are a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. We are seeking to develop IRX‑2, a novel cytokine-based therapy, to treat patients with cancer. IRX‑2 active constituents, namely Interleukin-2, or IL‑2, and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells, unlike existing cancer therapies, which rely on targeting the cancer directly. We also are exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using gene-editing cell‑therapy technology through a license with Factor Biosciences Limited and Novellus Therapeutics Limited, which we refer to collectively as the Licensor.
The development of our product candidates could be disrupted and materially adversely affected by the continuing COVID-19 pandemic. As a result of measures imposed by the governments in affected regions, businesses and schools have been suspended due to quarantines intended to contain this outbreak. The spread of SARS CoV‑2 from China to other countries resulted in the Director General of the World Health Organization declaring COVID-19 a pandemic that began in March 2020, over 1 million hours2020. While the constraints of trivia, card, sports and arcade games were played on our network each month.

We generate revenue by charging subscription fees to our partners for access to our 24/7 trivia network, by selling and leasing tablet and hardware equipment for custom usage beyond trivia/entertainment, by selling digital-out-of-home (DOOH) advertising direct to advertisers and on national ad exchanges, by licensing our entertainment and trivia content to other parties, and by providing professional services such as custom game design or development of new platforms on our existing tablet form factor. Up until February 1, 2020,the pandemic are slowly being lifted, we also generated revenue by hosting live trivia events (see Note 5 toare still assessing the consolidated financial statements included in Item 1 of this report).

We own several trademarks and consider the Buzztime®, Playmaker®, Mobile Playmaker, and BEOND Powered by Buzztime trademarks to be among our most valuable assets. These and our other registered and unregistered trademarks used in this document are our property. Other trademarks are the property of their respective owners.

Unless otherwise indicated, references in this report: (a) to “Buzztime,” “NTN,” “we,” “us” and “our” refer to NTN Buzztime, Inc. and its consolidated subsidiaries; (b) to “network subscribers,” “customers,” or “partners” refer to venues that subscribe to our network service; (c) to “consumers,” “patrons” or “players” refer to the individuals that engage in our games, events, and entertainment experiences available at venues and (d) to “venues” or “sites” refer to locations (such as a bar or restaurant) of our customers at which our games and entertainment experiences are available to consumers.

Recent Developments

COVID-19 Impact Update

The negativelonger term impact of the COVID-19 pandemic on our development plans, and on the restaurant and bar industry was abrupt and substantial, andability to conduct our clinical trials There can be no assurance that this analysis will enable us to avoid or remediate part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business cash flows from operations and liquidity suffered, and continuessentiment generally. The extent to suffer, materially as a result. In many jurisdictions, including those in which we have many customers and prospective customers, restaurants and bars have been ordered by the government to shut down or close all on-site dining since the latter half of March 2020. At its peak, approximately 70% of our customers requested that their subscriptions to our services be temporarily suspended. As governmental orders and restrictions impacting restaurants and bars are eased or lifted, we expect the temporary subscription suspensions to end, however, even in jurisdictions in which such orders and restrictions are eased or lifted, our customers could request to continue their subscription suspensions if, for example, such customers choose not to re-open despite being permitted to do so. We have experienced material decreases in subscription revenue, advertising revenue and cash flows from operations, which we expect to continue for at least as long as the restaurant and bar industry continues to be negatively impacted by the COVID-19 pandemic and global efforts to contain its spread will impact our operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID‑19 pandemic.

The patients in our clinical trials have conditions that make them especially vulnerable to COVID-19, and as a result we have seen slowdowns in enrollment in our clinical trials. While our Phase 2b clinical study in patients with squamous cell carcinoma of the oral cavity, known as the INSPIRE study, is fully populated, our other clinical studies are likely to continue to encounter delays as a result of the pandemic. Further, with respect to the INSPIRE study, we anticipate that the COVID-19 pandemic will slow our ability to close out trial sites and report trial data.
IRX‑2 is a therapy based on IL‑2, a type of cytokine-signaling molecule in the immune system. While many of the mechanisms of action of COVID-19 are still unknown, there is evidence that for some patients, severe COVID-19 patients may continue thereafter if restaurants and bars seek to reduce their operating costs or are unable to re-open even if restrictions within their states are lifted. We cannot predict with certainty whether, when or the mannerresult in “cytokine storm syndrome,” in which the impactbody releases cytokines into the body too quickly, which can create symptoms such as high fever, inflammation, severe fatigue and nausea and can lead to severe or life-threatening symptoms.
In June 2020 the Journal of Medical Virology published a letter submitted by Wen Luo, Jia-Wen Zhang, Wei Zhang, Yuan-Long Lin and Qi Wang, supported by grants from the State Key Laboratory of Veterinary Technology, Harbin Veterinary Research Institute, stating that, based on a review of 25 patients admitted to intensive care units with a confirmed infection of COVID-19, cytokine storm of a number of interleukins, including IL‑2, was absent. The letter therefore suggested that the severity of COVID-19 symptoms is not directly associated with circulating levels of IL‑2. There can be no assurance, however, that further study will bear this out or that patients treated with IRX‑2, who are already at higher risk for COVID-19 due to their underlying diagnosis, will not be adversely affected.
IRX‑2 is a primary human cell-derived biological medicinal product containing multiple active cytokine components acting as immunomodulators. It is prepared from the supernatant of pooled allogeneic peripheral blood mononuclear cells, known as PBMNCs, that have been stimulated using a proprietary process employing a specific population of cells and a specific mitogen.
While IRX‑2 is a cytokine mixture, one of its principal active components is IL‑2, a cytokine-signaling molecule in the immune system. IL‑2 is a protein that regulates the activities of white blood cells (leukocytes and often lymphocytes) that are responsible for immunity. IL‑2 is part of the pandemic will improve, includingbody’s natural response to microbial infection, and in discriminating between foreign (“non-self”) and “self,” IL‑2 mediates its effects by binding to IL‑2 receptors, which are expressed by lymphocytes. The major sources of IL‑2 are activated CD4+ T cells and activated CD8+ T cells.
Unlike existing recombinant IL‑2 therapies, IRX‑2 is naturally derived from human blood cells. This potentially may promote better tolerance, broader targeting and a natural molecular conformation leading to greater activity, and may permit low physiologic dosing, rather than the high doses needed in other existing IL‑2 therapies. Our ongoing development program is specifically investigating use of IRX‑2 in neoadjuvant (pre-surgical) and adjuvant (post-operative) treatment for advanced head and neck squamous cell carcinoma, or HNSCC. IRX‑2 has received both fast track designation and orphan drug designation from the U.S. Food and Drug Administration, or FDA, for this indication. Potential use of our product candidate in other cancer indications is also being evaluated in several investigator-sponsored trials. Finally, we are currently modifying our manufacturing process to allow us to develop additional drugs with a variety of cytokine mixtures to expand our product offerings.
Our product candidate IRX‑2 currently remains under development and has not yet been approved for marketing authorization in any jurisdiction. The ongoing development program is investigating use of IRX‑2 as an immunotherapeutic neoadjuvant (pre-surgical) and adjuvant (post-operative) treatment for advanced HNSCC and other indications.
The HNSCC development program is being conducted under FDA Investigational New Drug #11,137 filed on June 30, 2003 and is ongoing. Potential use of IRX‑2 in other cancer indications is also being conducted by independent clinical researchers as investigator‑initiated trials.
The HNSCC program has received fast track designation, approved November 7, 2003, and orphan drug designation, conferred on July 7, 2005, from the FDA. We have not submitted a request for orphan drug designation in the European Union, though we may seek such designation in the future.
Our findings to date from nonclinical studies of IRX‑2 include murine acute toxicology as well as acute and chronic primate studies. These studies detected circulating associated cytokines yet were associated with benign toxicological findings. A further murine study demonstrated PD/PDL‑1 synergy when restaurants willadditively administered with IRX‑2.
Clinical studies in humans involving IRX‑2 show immune marker activation in patients treated with IRX‑2. In a prior clinical trial, a correlation was shown between marker activation and disease-free survival in head and neck cancer.
Our clinical pipeline of therapeutic studies focused on oncology indications of high unmet medical need includes:
Monotherapy studies:
INSPIRE, a Phase 2B study involving 105 patients with HNSCC. Details of this trial can be permitted to offer on-site dining or when bars willfound at clinicaltrials.gov (NCT02609386).
BR-101 - A study involving 16 patients with neoadjuvant breast cancer performed at the Providence Portland Medical Center. Details of this trial can be permitted to re-open or to what degree, when our customers will re-open, or if they will subscribe to our service if and when they do, or if and when there will be a resurgence in COVID-19 transmission or infection after the easing or lifting of stay-at-home orders, and if there is, the impact of such resurgence on our business. Similarly, we cannot predict with certainty the durationfound at clinicaltrials.gov (NCT02950259).
CIN-201 - An open label single arm Phase 2 trial of the IRX‑2 regimen in women with cervical squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neoplasia 3. Details of this trial can be found at clinicaltrials.gov (NCT03267680).
Combination studies:
BAS-104 - A basket study originally intended to enroll 100 patients with metastatic bladder, renal, non-small cell lung cancer (NSCLC), melanoma, and head and neck cancer being held at the Moffitt Cancer Center, using IRX‑2 in conjunction with Opdivo (Nivolumab), an immunotherapy cancer treatment marketed by Bristol-Myers Squibb Company. Details of this trial can be found on clinicaltrials.gov (NCT03758781).
HCC-107 - A study involving 28 patients with metastatic hepatocellular carcinoma, HCC, being held at HonorHealth Research Institute, City of Hope Medical Center and Texas Oncology at Baylor Charles A. Simmons Cancer Center using IRX‑2 in conjunction with Opdivo, a cancer treatment marketed by Bristol-Myers Squibb Company. Details of this trial can be found at clinicaltrials.gov (NCT03655002).
GI-106 - A study involving 20 patients with metastatic gastric and gastroesophageal junction cancers (GI) being held at HonorHealth Research Institute, City of Hope Medical Center and Texas Oncology at Baylor Charles A. Simmons Cancer Center using IRX‑2 in conjunction with Keytruda (Pembrolizumab), an immunotherapy cancer treatment marketed by Merck. Details of this trial can be found at clinicaltrials.gov (NCT03918499).
MHN-102 - A study involving 15 patients with metastatic head and neck cancer being held at the H. Lee Moffitt Cancer Center and Research Institute and University of Michigan Health System using IRX‑2 in conjunction with Imfinzi (Durvalumab), a cancer treatment marketed by AstraZeneca plc. Details of this trial can be found at clinicaltrials.gov (NCT03381183).
BR-202 - A study involving 30 patients with neoadjuvant triple negative effectsbreast cancer, held at the Providence Portland Medical Center using IRX‑2 in conjunction with a programmed cell death protein 1 (PD1) and chemotherapy treatments. Details of this trial can be found at clinicaltrials.gov (NCT04373031).
Other than the INSPIRE study, each of the pandemic onstudies described above is an investigator-sponsored study for which we are providing IRX‑2 as study drug and financial support to conduct the trial.
Our strategy is twofold: to rapidly advance our businessIRX 2 platform to become a leader in immunologic therapy for various types of cancer as both a first-line therapy and liquidity, however, unlessin combination with other cancer treatments, and to commercialize the gene editing technology licensed from the Licensor:
Pursue commercialization of gene-editing technology. Develop analog mRNA based technology and proprietary delivery system licensed from the Licensors for gene therapy, and cellular engineering in the very near termtreatment of indications of high unmet medical need in oncology and other conditions.
Advance our subscription revenue, advertising revenue and cash flows from operations return to pre-pandemic levels and/or we raise substantial capital, the amountproduct candidate IRX 2 through clinical development. IRX 2 is a human blood-based IL 2 therapy being studied for multiple types of time and the amount of cash we have to maintain operations and sustain the negative effectscancer, including squamous cell cancer of the pandemic is very limited. See “—Liquidityhead and Capital Resources,” below,neck. Treatment of patients in the INSPIRE trial has been completed, and “Item 1A. Risk Factors”patients who participated in Part IIthe trial are currently being monitored for event-free survival with top-line data estimated to be available in the first half of this report2022.
Advance combination trials with checkpoint inhibitors. Once INSPIRE trial are released, we plan to use those results as a catalyst in addition to six other clinical trials with multiple data read-outs anticipated in 2022 and later.
Pursue partnerships to advance our clinical program. We are pursuing partnering opportunities with leading biopharmaceutical companies for the development and commercialization of IRX 2.
Opportunistically in-license/acquire complementary programs. We may seek additional products to license or acquire in order to expand our product pipeline. This includes products that we may seek to develop if we exercise our option to exclusively license certain additional technology from the Licensors.
Regulatory Strategy. We believe that our assets may be deemed to be unique and to represent potential breakthroughs in cancer treatment. We will endeavor to seek breakthrough therapy designation with regulatory agencies for IRX 2 for one or more indications and for any other product we may acquire or in license that could potentially lead to accelerated clinical development timelines. We cannot, however, assure you that we will receive breakthrough therapy designation for any indications or that any breakthrough therapy designation we do receive will necessarily lead to a faster approval time.
Intellectual Property. We continue to pursue additional intellectual property based on data from IRX clinical studies.
For additional information regarding the impact of the pandemic on our business, and outlook.

Our current focus is on maintaining operations and at this time we are no longer focusing on the areas in which we intended to focus during 2020 as reported in the section titled, “Our Strategy,” in ITEM 1. Businessplease see Item 8.01 of our 2019 10-K.

Paycheck Protection Program Note

InCurrent Report on Form 8-K filed with the SEC on May 11, 2021.

Recent Developments
License Agreements with the Licensor
On April 2020, we received a $1,625,100 loan under the Paycheck Protection Program of the Coronavirus Aid, Relief, and Economic Security Act administered by the U.S. Small Business Administration. The loan matures on April 18, 2022 and bears interest at a rate of 1.0% per annum. We must make monthly interest only payments beginning on November 18, 2020. One final payment of all unforgiven principal plus any accrued unpaid interest is due at maturity. See “—Liquidity and Capital Resources,” below.

Amended Loan and Security Agreement

On March 12, 2020, we 26, 2021 , Brooklyn LLC entered into an amendmentexclusive license agreement, or the License Agreement, with the Licensor to license the Licensor’s IP and mRNA cell reprogramming and gene editing technology for use in the development of certain cell-based therapies to be evaluated and developed for treating human diseases, including certain types of cancer, sickle cell disease, and beta thalassemia. Through the License Agreement, Brooklyn LLC acquired an exclusive worldwide license to develop and commercialize certain cell-based therapies to treat cancer and rare blood disorders, including sickle cell disease, based on patented technology and know-how of Novellus Therapeutics Limited.

The License Agreement provides that Brooklyn LLC is obligated to pay the Licensor a total of $4,000,000 in connection with the execution of the License Agreement, of which $2,500,000 has been paid and the remaining $1,500,000 is expected to be paid in July 2021. Brooklyn LLC is obligated to pay to the loanLicensor additional fees of $5,000,000 in October 2021 and security agreement that we entered into with Avidbank$7,000,000 in September 2018 for a $4,000,000 four-year term loan. In connection with entering into the amendment, we made a $433,000 payment on our term loan, which includes the $83,333 monthly principal payment plus accrued interest for March 2020 and a $350,000 principal prepayment, thereby reducing the outstanding principal balance of our term loan to $2.0 million. Additionally, underOctober 2022.
Under the terms of the amendment,License Agreement, Brooklyn LLC is required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of these milestones, Brooklyn LLC will be obligated, in the maturitycase of development and regulatory milestones, to make milestone payments to Licensor in specified amounts and, in the case of commercialization milestones, to specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Brooklyn LLC fails to timely achieve certain delineated milestones, the Licensor may have the right to terminate the rights of Brooklyn LLC under provisions of the License Agreement relating to those milestones.
The Licensor is responsible for preparing, filing, prosecuting and maintaining all patent applications and patents under the License Agreement. If, however, the Licensor determines not to maintain a particular licensed patent or not to prepare, file and prosecute a licensed patent, Brooklyn LLC will have the right, but not the obligation, to assume those responsibilities in the territory at its expense.
Novellus is a pre-clinical development, manufacturing, and technology licensing entity focused on engineered cellular medicines. Novellus has created, developed, and patented mRNA-based cell reprogramming and gene editing technologies to create engineered cellular medicines. The synthetic mRNA developed by Novellus is non-immunogenic—it is capable of successfully evading the immune system while being recognized by cellular processes. The synthetic mRNA is then capable of expressing high levels of proteins for cell reprogramming and gene editing. The mRNA may be formulated for injection into target tissues for cellular uptake and therapeutic treatment.
The synthetic mRNA technology may be used to edit gene mutations through mRNA chemistry or expressed gene-editing proteins to treat genetic and rare diseases. It may also be used to reprogram human non-pluripotent cells and induce human pluripotent stem cells, or IPSCs. The IPSCs may then be differentiated into pure populations of varying therapeutic cell types. The reprogramming technology offers a rapid, cost-effective and patient specific therapy using the engineered stem cells created from IPSCs.
Novellus has over 45 granted patents throughout the world covering synthetic mRNA, RNA-based gene editing, and RNA-based cell reprogramming, in addition to specific patents covering methods for treating specific diseases. There are also greater than 50 pending patent applications throughout the world focused on these and other aspects of the technology. The patent coverage includes granted patents and pending patent applications in the United States, Europe, and Japan along with other major life sciences markets.
There can be no assurance that Brooklyn LLC can successfully develop and commercialize the technology licensed under the License Agreement.
Purchase Agreement
On April 26, 2021, we entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, under which, subject to specified terms and conditions, we may sell to Lincoln Park up to $20.0 million of shares of common stock from time to time during the term of the Purchase Agreement.
Additionally, on April 26, 2021, we entered into a registration rights agreement, or the Registration Rights Agreement, with Lincoln Park, pursuant to which we agreed to file a registration statement with the Securities and Exchange Commission, or the SEC, covering the resale of shares of common stock issued to Lincoln Park under the Purchase Agreement.
Under the terms and subject to the conditions of the Purchase Agreement, we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $20.0 million of shares of common stock. Any such sale of common stock will be subject to specified limitations and may occur from time to time, at our discretion, over a 36-month period commencing after the date that a registration statement covering the resale of shares of common stock issued under the Purchase Agreement, which we agreed to file with the SEC pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith is filed and the other conditions set forth in the Purchase Agreement are satisfied. Lincoln Park has no right to require us to sell any common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as we direct, subject to conditions set forth in the Purchase Agreement.
Upon entering into the Purchase Agreement, we issued and sold 56,041 shares of common stock, or the Commitment Shares, to Lincoln Park as consideration for Lincoln Park’s commitment to purchase up to $20.0 million shares of common stock under the Purchase Agreement.
Under the Purchase Agreement, we may elect from time to time, subject to specified conditions, to require the selling stockholder to purchase on any single business day on which the closing price of common stock is equal to or greater than $1.00, which we refer to as a Regular Purchase, (a) up to 60,000 shares of common stock, (b) if the closing sale price of common stock on the NYSE American is at least $5.50 per share, up to 80,000 shares of common stock or (c) if the closing sale price of common stock on the NYSE American is at least $7.00 per share, up to 120,000 shares of common stock. In no case, however, will the selling stockholder’s commitment with respect to any single Regular Purchase exceed $1,000,000. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of our term loan was changedthe Purchase Agreement with respect to common stock. The purchase price per share for each such Regular Purchase will be based on prevailing market prices of the common stock immediately preceding the time of sale, as determined under the Purchase Agreement.
In addition to Regular Purchases, we may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases on the terms and subject to the conditions set forth in the Purchase Agreement.
As of May 14, 2021, we had issued and sold an aggregate of 302,358 shares of common stock to Lincoln Park pursuant to the Purchase Agreement, resulting in gross proceeds of $6.3 million.
Basis of Presentation
Revenues
We are a development stage company and have had no revenues from September 28, 2022product sales to December 31, 2020, and the amount and timingdate. We will not have revenues from product sales until such time as we receive regulatory approval of our payment obligations accelerated significantly.

Other

In January 2020, we solddrug candidates, successfully commercialize our products or enter into a licensing agreement which may include up-front licensing fees, of which there can be no assurance.

General and Administrative Expenses
Our general and administrative expenses consist primarily of salaries, benefits and other costs, including stock-based compensation, for our executive and administrative personnel, legal and other professional fees; travel, insurance, and other corporate costs.
Research and Development Expenses
Our research and development expenses consist of costs incurred for company-sponsored research and development activities, as well as support for selected investigator-sponsored research. The major components of research and development costs include preclinical study costs, clinical manufacturing costs, clinical study and trial expenses, insurance coverage for clinical trials, consulting, scientific advisors and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and materials (required capital equipment) and allocations of various overhead costs related to our product development efforts. To date, all of our assets usedresearch and development resources have been devoted to conduct the live-hosted knowledge-based trivia events known as Stump! Triviadevelopment of IRX-2, and OpinioNation for approximately $1.4 million in cash.

Strategic Process

Our board of directors continueswe expect this to explore and evaluate strategic alternatives focused on maximizing shareholder value, while also exploring and evaluating financing alternatives to increase the likelihood that we will be able to avoid a restructuring, which may include a reorganization, bankruptcy, assignmentcontinue for the benefitforeseeable future.

In the normal course of creditors, or a dissolution, liquidation and/or winding up,our business, we contract with third parties to perform various clinical study and trial activities in the event the strategic process does noton-going development and testing of potential products. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in a transaction. Our boarduneven payment flows. Payments under the contracts depend on factors such as the achievement of directors has not set a timetable forcertain events or milestones, the strategic process nor has it made any decisions relating to any strategic alternatives at this time, and no assurance can be given assuccessful enrollment of patients, the allocation of responsibilities among the parties to the outcomeagreement, and the completion of portions of the process.clinical study or trial or similar conditions. Preclinical and clinical study and trial associated activities such as production and testing of clinical material require significant up-front expenditures. We do not intend to discloseanticipate paying significant portions of a study or trial’s cost before such begins and incurring additional details regardingexpenditures as the strategic process unlessstudy or trial progresses and until further disclosure is appropriate or necessary.

reaches certain milestones.

CRITICAL ACCOUNTING POLICIES34

The


Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”).GAAP. The preparation of these consolidated financial statements requires us to make judgments, estimates, and judgmentsassumptions that affect the reported amounts of assets and liabilities revenues and expenses, and relatedthe disclosure of contingent assets and liabilities. On an ongoing basis, weliabilities at the date of the consolidated financial statements, as well as the reported revenue and expenses during the reporting periods. We continually evaluate our judgments, estimates including those related to deferred costs and revenues, depreciation and amortization of fixed assets, the provision for income taxes including the valuation allowance, stock-based compensation, bad debts, impairment of software development costs, goodwill, intangible assets and contingencies.assumptions. We base our estimates on the terms of underlying agreements, our expected course of development, historical experience and on various other assumptionsfactors we believe to beare reasonable underbased on the circumstances, the results of which form theour management’s basis for making judgments about the carrying valuesvalue of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates underestimates.
The accounting policies described below are not intended to be a comprehensive list of all of our accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP. There are also areas in which our management’s judgment in selecting any available alternative would not produce a materially different assumptions or conditions. Criticalresult. Our consolidated financial statements and the notes thereto included elsewhere in this report contain accounting policies and other disclosures as required by GAAP.
Use of Estimates
We are required under GAAP to make estimates and assumptions that affect (a) the reported amounts of assets and liabilities, (b) disclosure of contingent assets and liabilities at the date of the financial statements, (c) the reported amounts of revenues and expenses during the reporting period, and (d) the reported amount of the fair value of assets required in connection with our business combination with IRX Therapeutics, LLC in 2018. Our actual results could differ, possibly significantly, from those estimates.
Cash and Cash Equivalents
Cash and cash equivalents are defined as thosea measure of our cash on hand and any highly liquid investments with maturity dates within the next three months. At December 31, 2020 and March 31, 2021, we had cash of $1.6 million and $8.4 million, respectively.
Property and Equipment
Property and equipment are recorded at cost on our balance sheets, and then are depreciated over their useful lives. Laboratory and manufacturing equipment are depreciated over an estimated 7-year life span. Leasehold improvements are depreciated over the shorter of their useful life, or the end of the lease term. When these assets are disposed of, the cost and related accumulated depreciation are removed from our balance sheet and the resulting gain or loss is recognized.
In-Process Research and Development
In-process research and development, or IPR&D, assets represent the fair value of the technologies acquired in connection with the business combination with IRX Therapeutics, LLC have not reached technological feasibility and likely have no alternative future use. IPR&D assets are considered to be indefinite lived until the associated research is completed or abandoned. If IPR&D assets are deemed to be indefinite, they are tested for impairment on an annual basis, or more frequently if we become aware of any events or changes that result in the fair value of these assets being decreased. In such a case, where we are both most importantable to commercialize IPR&D assets, the lives of the assets are reduced and the amounts are amortized based on the estimated useful lives beginning at that point in time. Where development is terminated or abandoned, there may be a small impairment charge related to the portrayalIPR&D assets.
Research and Development
Research and development expenses are charged to operations as incurred. These assets include costs related to clinical and preclinical trials such as payments to coordinators and hospitals, costs of testing and other medical procedures provided to patient test subjects, site visits, and other costs related to our clinical trials.
Income Taxes
We were not directly subject to federal, state or local income taxes through December 31, 2018, as any tax liability was passed on to our members. In the year ended December 31, 2019, we recorded taxable income related to the New York City Unincorporated Business Tax. We expect this to continue in the future.

The benefits from uncertain tax positions are recognized only if it is more likely than not that the position will be sustained upon examination by local, state or federal taxing authorities. Any tax benefits recognized in our financial condition and results and require management’s most subjective judgments.

Therestatements are measured based on the largest benefit that has at least a 50% likelihood of being realized. At this time, we have been no material changes in our critical accounting policies, estimates and judgments during the three months endeduncertain tax positions for any recording period.

Results of Operations
Comparison of Three Months Ended March 31, 2020 from those described in the “Management’s Discussion2021 and Analysis of Financial Condition and Results of Operations” section of our 2019 10-K.

RESULTS OF OPERATIONS

2020


  For the three months ended March 31,       
  2021  2020  Change $  Change % 
             
Operating Expenses:            
Research and development $1,519,633  $(38,971)  1,558,604   -3999%
General and administrative  1,636,557   1,053,505   583,052   55%
Transaction costs  5,765,407   -   5,765,407   N/A 
Change in fair value of contingent consideration  (820,000)  -   (820,000)  N/A 
Total operating expenses  8,101,597   1,014,534         
Loss from operations  (8,101,597)  (1,014,534)        
Other Expenses:                
Other expense, net  (2,564)  (4,678)  2,114   -45%
Loss on sales of NTN assets  (9,598,173)  -   (9,598,173)  N/A 
Total other expenses  (9,600,737)  (4,678)        
Net loss attributable to common stockholders $(17,702,334) $(1,019,212)        

Revenues
We incurred a net loss of $1,218,000had no revenues for the three months ended March 31, 2020, compared2021 or 2020.
General and Administrative Expenses
General and administrative expenses include corporate and office expenses, legal, accounting and consulting fees, and travel expenses. Our general and administrative expenses increased due to additional fees for professional and legal fees associated with the Merger.
We expect general and administrative expenses to increase in future periods as we increase our business activities following completion of the Merger and incur costs associated with being a net losspublicly traded company.
Research and Development Expenses
Research and development expenses in 2021 relate to the support of $313,000 forour investigator-sponsored studies.
Expenses related to our research and development activities increased during the three months ended March 31, 2019.

Revenue

21, 2021 when compared against the same period in 2020 due to stock-based compensation modification for the conversion of common units into common shares and increase in clinical trials for new trial initiation.

We generate revenue by charging subscription feesexpect research and development expenses to grow as we expand our partners for access to our 24/7 trivia network, by selling and leasing tablet and hardware equipment for custom usage beyond trivia/entertainment, by selling digital-out-of-home (DOOH) advertising direct to advertisers and on national ad exchanges, by licensing our entertainment and trivia content to other parties, and by providing professional services such as custom game design or development of new platforms on our existing tablet form factor. Up until February 1, 2020, we also generated revenue by hosting live trivia events (see Note 5 to the consolidated financial statements included in Item 1 of this report). The table below summarizes the type of revenue we generatedclinical trial activities.
Transaction Costs
There were no transaction costs for the three months ended March 31, 2020 and 2019 and the change in such revenue between the two periods:

  Three months ended March 31,       
  2020  2019       
  $  % of Total Revenue  $  % of Total Revenue  $ Change  % Change 
Subscription revenue  1,999,000   83.5%  3,833,000   79.3%  (1,834,000)  (47.8)%
Hardware revenue  16,000   0.7%  205,000   4.2%  (189,000)  (92.2)%
Other revenue  379,000   15.8%  794,000   16.5%  (415,000)  (52.3)%
Total  2,394,000   100.0%  4,832,000   100.0%  (2,438,000)  (50.5)%

Subscription Revenue

The decrease in subscription revenue for the three months ended March 31, 2020 was primarily due to lower average site count and lower average revenue per site when compared to the same period in 2019. We previously reported that our subscription revenue would materially decrease beginning in the first quarter of 2020 if we did not add network subscribers or other revenue sources sufficient to replace the revenue historically received from Buffalo Wild Wings corporate-owned restaurants and its franchisees, after our existing relationships with BWW terminated in November 2019. To date, we have not offset the lost subscription revenue from Buffalo Wild Wings corporate-owned restaurants and its franchisees.

Because shelter-in-place orders and governmental orders for restaurants and bars to shut down or close all on-site dining were generally issued toward the end of the first quarter of 2020, we expect the negative impacts of the COVID-19 pandemic on our subscription revenue to be significantly greater in the second quarter of 2020 compared to the first quarter of 2020. At its peak, approximately 70% of our customers requested that their subscriptions to our services be temporarily suspended. As governmental orders and restrictions impacting restaurants and bars are eased or lifted, we expect the temporary subscription suspensions to end, however, even in jurisdictions in which such orders and restrictions are eased or lifted, our customers could request to continue their subscription suspensions if, for example, such customers choose not to re-open despite being permitted to do so. See “Item 1A. Risk Factors” in Part II of this report for additional information regarding the impact of the pandemic on our business and outlook.

The table below provides a geographic breakdown of our site count as of the date indicated:

  Network Subscribers as of March 31, 
  2020  2019 
United States  1,277   2,491 
Canada  119   141 
Total  1,396   2,632 

Hardware Revenue

The decrease in hardware revenue for the three months ended March 31, 2020 was primarily due to decreased sales-type lease arrangements when compared to the same period in 2019. As previously reported, we did not, and do not, expect to continue recognizing hardware revenue under sales-type lease arrangements during 2020 or thereafter. Unless we license or otherwise dispose of our hardware business, we expect to continue recognizing hardware revenue throughout 2020 under our existing contract from our jail services partner, however, we are uncertain if we will enter into another equipment sale contract with our jail services partner or any other party. We are in early stage discussions to license our hardware business to a third party to help preserve capital as the cost to service this revenue stream is significant relative to our existing cash on hand.

Other Revenue

The decrease in other revenue for the three months ended March 31, 2020 was primarily due to a decrease in revenue from our live-hosted trivia events when compared to the same period in 2019 as a result of the sale of all our assets used to conduct the live-hosted knowledge-based trivia events known as Stump! Trivia and OpinioNation in January 2020. We do not expect to recognize revenue from live-hosted trivia events in the future. We also recognized less license revenue and advertising revenue during the three months ended March 31, 2020 when compared to the same period in 2019. We expect our advertising revenue will continue to be materially adversely impacted because of a decrease in advertising sales arising from a slowdown in consumer traffic of the restaurant and bars that subscribe to our service as a result of the COVID-19 pandemic.

Direct Operating Costs and Gross Margin

A comparison of direct costs and gross margin for the periods indicated is shown in the table below:

  For the three months ended March 31,       
  2020  2019  Change  % Change 
Revenues $2,394,000  $4,832,000  $(2,438,000)  (50.5)%
Direct Costs  950,000   1,484,000   (534,000)  (36.0)%
Gross Margin $1,444,000  $3,348,000  $(1,904,000)  (56.9)%
                 
Gross Margin Percentage  60.3%  69.3%        

For the three months ended March 31, 2020, the decrease in directtransaction costs was primarily due to (1) decreases in direct wages of approximately $199,000 as a result of no longer providing live-hosted trivia events after January 2020 duerelated to the saleissuance of allcommon stock to our assets used to conductfinancial advisor upon consummation of the live-hosted knowledge-based trivia events discussed above; (2) decreased depreciation expenseMerger.

Change in Fair Value of $190,000; and (3) decreased service provider and freight expenseContingent Consideration
Change in fair value of approximately $89,000; (4) decreased license fees of $39,000; and (5) decreased other miscellaneous expenses of $16,000, in each case, when compared to the same period in 2019.

The decrease in gross margincontingent consideration was $820,000 for the three months ended March 31, 2020 was primarily due to revenue mix2021 and writing off approximately $188,000 in older technology equipment$0 for the three months ended March 31, 2020 when compared to the same period in 2019.

Operating Expenses

  For the three months ended March 31,       
  2020  2019  Change  % Change 
Selling, general and administrative $3,080,000  $3,468,000  $(388,000)  (11.2)%
                 
Impairment of capitalized software $138,000  $1,000  $137,000   13,700.0%
                 
Impairment of goodwill $662,000  $-  $662,000   100.0%
                 
Depreciation and amortization (non-direct) $85  $96  $(11)  (11.5)%

Selling, General and Administrative Expenses

The decrease in selling, general and administrative expenses2020.

Other Expense, Net
Other expense, net for the three months ended March 31, 2021 and 2020 was primarily duemainly related to decreased (1) payroll and related expensepayments of $283,000, (2) marketing feesinterest on notes in the principal amount of $198,000 and (3) professional fees of $60,000 due to fewer consulting expenses. These decreases were partially offset by increased bad debt expense of $159,000. In light$410,000 that we assumed as part of the recent measures we implementedacquisition of the assets of IRX Therapeutics, LLC in 2018. The notes bear interest at the rate of 14% and were due on December 31, 2019. On January 27, 2020, the notes were amended to reduce operating expensesextend the maturity date to the earlier of (i) a change of control and to preserve capital, we expect our selling, general and administrative expenses to decrease in 2020. However, such actions, and any similar actions we may implement in the future, could adversely affect our business and we may not realize the operation or financial benefits(ii) December 31, 2021, whichever comes first.
Loss on Sales of such actions.

ImpairmentNTN Assets

Loss on sales of Capitalized Software

Impairment of capitalized software increasedNTN assets for the three months ended March 31, 20202021 was incurred when we completed the Asset Sale.


Liquidity and Capital Resources
Since our inception, we have financed our operations primarily with capital calls to our members. At March 31, 2021, we had cash and cash equivalents of $8.4 million principally derived from contributions by our members. We have to date incurred operating losses, and we expect these losses to increase in the future as we expand our drug development programs and operate as a publicly traded company. We anticipate using current cash on hand and our net proceeds from sales of common stock under the Purchase Agreement to finance these activities. It will likely be some years before we obtain the necessary regulatory approvals to commercialize one or more of our drug candidates. Based on our current financial condition and forecasts of available cash, including as mentioned above, we believe we have sufficient funds to fund our operations through the first quarter of 2022. There can be no assurance that we will ever be in a position to commercialize IRX-2 or any other drug candidate we may acquire, or that we will obtain any additional financing that we require in the future or, even if such financing is available, it will obtainable on terms acceptable to us.
In that regard, our future funding requirements will depend on many factors, including:
the scope, rate of progress and cost of our clinical trials and other product development activities;
future clinical trial results;
the terms and timing of any collaborative, licensing and other agreements that we may establish;
the cost and timing of regulatory approvals;
the cost and delays in product development as a result of abandoning certain capitalized softwareany changes in regulatory oversight applicable to our products;
the cost and timing of establishing sales, marketing and distribution capabilities;
the effect of competition and market developments; and
the cost of filing and potentially prosecuting, defending and enforcing any patent claims and other intellectual property rights.
We plan to raise additional funds to support our product development projectsactivities and working capital requirements through public or private equity offerings, debt financings, corporate collaborations or other means. We may also seek governmental grants to support our clinical trials and preclinical trials. Further, we may seek to raise capital to fund additional product development efforts even if we have sufficient funds for our planned operations. Any sale by us of additional equity or convertible debt securities could result in dilution to our stockholders. There can be no assurance that any such required additional funding will be available to us at all or available on terms acceptable to us.
Further, to the extent that we concluded were no longerraise additional funds through collaborative arrangements, it may be necessary to relinquish some rights to our technologies or grant sublicenses on terms that are not favorable to us. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs, which could have an adverse effect on our business.
Sources of Funds
Equity Securities
As a current strategic fit or for which we determined thatcondition to the marketabilityclosing of the content had decreased due to obtaining additional information regarding the specific purpose for which the content was intended.

Impairment of Goodwill

We have goodwill resulting from the excess of costs over the fair value of assetsMerger, we acquired in 2003 related to our Canadian business (the “Reporting Unit”). Goodwill and intangible assets acquired in a purchase combination that are determinedwere required to have an indefinite useful life are not amortized, but instead are assessed annually, or at interim periods, for impairment based on qualitative factors, such as macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events, to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of the Reporting Unit is less than its carrying amount. If there are indications of impairment, then we perform a quantitative impairment test.

During the Company’s evaluation of impairment indicators as of March 31, 2020, we determined that the uncertainty relating to COVID-19’s impact on the Reporting Unit’s future operating results represented an indicator of impairment. Accordingly, we compared the estimated fair value of the Reporting Unit to its carrying value at March 31, 2020, determined that a full impairment loss was warranted and recognized an impairment charge of $662,000 for the three months ended March 31, 2020. There was no goodwill impairment recorded for the three months ended March 31, 2019.

Depreciation and Amortization

The decrease in depreciation and amortization expense for the three months ended March 31, 2020 was primarily due to various equipment becoming fully depreciated and not replacing with new assets.

Other Income (Expense), Net

  For the three months ended March 31,  Increase in other 
  2020  2019  income, net 
Total other income (expense), net $1,284,000  $(85,000) $1,369,000 

For the three months ended March 31, 2020, the increase in other income (expense), net, was primarily due to a $1,265,000 gain related to the asset sale of all our assets used to conduct the live-hosted knowledge-based trivia events, increased foreign currency gains related to our Canadian subsidiary, and decreased interest expense due to lower long-term debt balances when compared to the same period in 2019.

Income Taxes

  For the three months ended March 31,       
  2020  2019  Change  % Change 
Benefit (provision) for income taxes $19,000  $(11,000) $30,000   (273)%

We expect to incur state income tax liability in 2020 related to our U.S. operations. For the three months ended March 31, 2020, an impairment to goodwill resulted in a in a net tax benefit in Canada. We have established a full valuation allowance for substantially all of our deferred tax assets, including the NOL carryforwards, since we do not believe we are likely to generate future taxable income to realize these assets

EBITDA—Consolidated Operations

Earnings before interest, taxes, depreciation and amortization, or EBITDA, is not intended to represent a measure of performance in accordance with GAAP. Nor should EBITDA be considered as an alternative to statements of cash flows as a measure of liquidity. EBITDA is included herein because we believe it is a measure of operating performance that financial analysts, lenders, investors and other interested parties find to be a useful tool for analyzing companies like us that carry significant levels of non-cash depreciation and amortization charges compared to their net income or loss calculation in accordance with GAAP.

The tables below shows a reconciliation of our consolidated net loss calculated in accordance with GAAP to EBITDA for the periods indicated. EBITDA should not be considered a substitute for, or superior to, net loss calculated in accordance with GAAP.

  For the three months ended March 31, 
  2020  2019 
Net loss per GAAP $(1,218,000) $(313,000)
Interest expense, net  45,000   67,000 
Income tax (benefit) provision  (19,000)  11,000 
Depreciation and amortization  546,000   747,000 
EBITDA $(646,000) $512,000 

LIQUIDITY AND CAPITAL RESOURCES

As of March 31, 2020, we had cash, cash equivalents and restricted cash of approximately $2.4 million (including the approximately $1.4least $10.0 million in cash we received in January 2020 from the sale of all our assets used to conduct our live-hosted knowledge-based trivia events) compared to cash,and cash equivalents at the effective time of the Merger. In furtherance of, and restricted cashprior to, the Merger, certain of approximately $3.4our members entered into agreements pursuant to which those members purchased units of Brooklyn LLC for an aggregate purchase price of $10.5 million.

On April 26, 2021, we entered into the Purchase Agreement under which, subject to specified terms and conditions, we may sell to Lincoln Park up to $20.0 million as of December 31, 2019.shares of common stock from time to time during the term of the Purchase Agreement. As discussedof May 14, 2021, we had issued and sold an aggregate of 302,358 shares of common stock to Lincoln Park pursuant to the Purchase Agreement, resulting in gross proceeds of $6.3 million. For further below, subsequentinformation, see “—Recent Developments—Purchase Agreement.”
Asset Sale. On March 26, 2021, we completed the Asset Sale, in which we sold to March 31, 2020,eGames.com our rights, title and interest in and to the assets relating to the business we received a loan of approximately $1.6 millionoperated prior to the Merger under the Paycheck Protection Program (the “PPP”)name “NTN Buzztime, Inc.” in exchange for eGames.com’s payment of a purchase price of $2.0 million and assumption of specified liabilities relating to such pre-Merger business.

Brooklyn PPP Loan. On March 27, 2020, then-President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act, (the “CARES Act”) administeredor the CARES Act, as amended on June 5, 2020 by the U.S. Small Business Administration.

In connection with preparing our financial statements asPaycheck Protection Program, or PPP. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carry back periods, and for the three months ended March 31, 2020, our management evaluated whether there are conditions or events, considered in the aggregate, that are known and reasonably knowable that would raise substantial doubt about our ability to continue as a going concern through twelve months after the date that such financial statements are issued. During the three months ended March 31, 2020, we incurred a net loss of $1,281,000, and our current liabilities exceeded our current assets at March 31, 2020 by $87,000. Since January 1, 2020, Avidbank required us to pay $750,000 of the principal balance of our term loan, thereby reducing it to $2,000,000 as of March 19, 2020. Under the terms of the amendment to our loan and security agreement that we entered into with Avidbank in March 2020, during 2020 we will be required to make monthly payments that, if made in accordance with their terms, will result in us paying off our term loan by December 31, 2020.

The negative impact of the COVID-19 pandemic on the restaurant and bar industry was abrupt and substantial, and our business, cash flows from operations and liquidity suffered, and continues to suffer, materially as a result. In many jurisdictions, including those in which we have many customers and prospective customers, restaurants and bars have been ordered by the government to shut down or close all on-site dining. At its peak, approximately 70% of our customers requested that their subscriptions to our services be temporarily suspended. As governmental orders and restrictions impacting restaurants and bars are eased or lifted, we expect the temporary subscription suspensions to end, however, even in jurisdictions in which such orders and restrictions are eased or lifted, our customers could request to continue their subscription suspensions if, for example, such customers choose not to re-open despite being permitted to do so. We have experienced material decreases in subscription revenue, advertising revenue and cash flows from operations, which we expect to continue for at least as long as the restaurant and bar industry continues to be negatively impacted by the COVID-19 pandemic, and which may continue thereafter if restaurants and bars seek to reduce their operating costs or are unable to re-open even if restrictions within their states are eased or lifted.

In responsealternative minimum tax credit refunds, modifications to the substantial negative impact of the pandemic on our business, we implemented measuresnet interest deduction limitations and technical corrections to reduce our operating expenses and preserve capital. We reduced our headcount (as oftax depreciation methods for qualified improvement property. On May 20, 2020, we have 17 employees compared to 74 at December 31, 2019) and our chief executive officer agreed to defer payment of 45% of all of his annual base salary payments between May 1, 2020 and October 31, 2020 until the earlier of October 31, 2020 or such time as our board of directors determines in good faith that we are in the financial position to pay his accumulated deferred salary. We eliminated all capital projects and are aggressively managing our payables and rent payments to limit further cash outlays and manage our working capital. We are continuing to carefully monitor our liquidity and our current focus is on maintaining operations. We are prioritizing payments to mission critical vendors and deferring all non-essential payables. We may implement additional measures designed to reduce operating expenses and/or preserve capital. We began discussions with Avidbank to modify our payment obligations under our term loan, to modify our financial covenants under our loan and security agreement and/or to obtain covenant relief. We also began discussions with our landlord to reduce or defer our rent payments, including vacating the space for an early termination of the lease. We are also in discussions with vendors to extend payment terms. We are unable to predict the outcome of these discussions or the extent to which we will be able to successfully modify our payment obligations or our financial covenants (or obtain covenant relief) related to our term loan, reduce or defer our rent payments, and/or extend vendor payment terms.

While we expect to meet our near term debt service obligations on our term loan with Avidbank and we satisfied our financial covenants under our related loan and security agreement as of March 31, 2020, unless in the very near term our subscription revenue, advertising revenue and cash flow from operations return to pre-pandemic levels and/or we raise substantial capital, we do not expect that we will be able to satisfy our asset coverage ratio covenant at the end of June 2020, which may result in Avidbank declaring a default under our loan and security agreement. As a result of the impact of the COVID-19 pandemic on our business and taking into account our current financial condition and our existing sources of revenue, unless in the very near term our subscription revenue, advertising revenue and cash flow from operations return to pre-pandemic levels and/or we raise substantial capital, we believe we will have sufficient cash resources to pay forecasted cash outlays through October 2020, assuming we deliver a significant hardware order as scheduled during the second quarter of 2020, Avidbank does not take actions to foreclose on our assets in the event we are out of compliance with our financial covenants, and we are able to continue to successfully manage our working capital deficit by managing the timing of payments to our vendors and other third parties.

We need in the very near term our subscription revenue, advertising revenue and cash flow from operations return to pre-pandemic levels, and/or we need to raise substantial capital in the very near-term to maintain operations. We continue to explore and evaluate opportunities to raise capital, including through equity financings, alternative sources of debt, and strategic transactions, which may include a business combination transaction and/or selling a portion or all of our assets. We currently have no arrangements for capital or for a strategic transaction, and no assurances can be given that we will be able to raise sufficient capital when needed, on acceptable terms, or at all, or that we will be able to complete a strategic transaction. If we are unable to raise sufficient additional capital in the very near term, we may default on our payment obligations to Avidbank or not satisfy our financial covenants to Avidbank, and if we do, Avidbank may declare a default, which could lead to all payment obligations becoming immediately due and payable and Avidbank has a first-priority security interest in all our existing and future personal property. In addition, we will be required to curtail or terminate some or all of our business operations and we may determine to pursue a restructuring, which may include a reorganization or bankruptcy under Federal bankruptcy laws, assignment for the benefit of creditors, or a dissolution, liquidation and/or winding up. Our investors may lose their entire investment in the event Avidbank forecloses on our personal property to satisfy our payment obligations and/or in the event of a reorganization, bankruptcy, assignment for the benefit of creditors, liquidation, dissolution or winding up.

See the risk factors titled, “Our cash flows from operations and liquidity have been materially adversely affected by the effects of the COVID-19 pandemic. We need to raise capital in the near term and our inability to do so could result in our lender foreclosing on all of our assets and/or us pursuing a restructuring, which may include a reorganization or bankruptcy under Federal bankruptcy laws, assignment for the benefit of creditors, or a dissolution, liquidation and/or winding up” and “If we fail to comply with our financial covenants to Avidbank, it may declare a default, which could lead to all payment obligations becoming immediately due and payable and have a material adverse effect on our financial condition and business,” in Item 1A. Risk Factors in Part II of this report, below.

Based on the factors described above, management concluded that there is substantial doubt regarding our ability to continue as a going concern through the twelve month period subsequent to the issuance date of these financial statements. Management’s plans for addressing the liquidity shortfall include continuing efforts to raise additional capital through equity financings and alternative sources of debt. However, there can be no assurances that we will be able to raise sufficient capital when needed, on acceptable terms, or at all.

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to our ability to continue as a going concern.

Avidbank Term Loan

Under a loan and security agreement we entered into with Avidbank in September 2018, or the Original LSA, we borrowed $4,000,000 in the form of a 48-month term loan, all of which we used to pay-off the $4,050,000 of principal borrowed from our then-existing lender. In February 2020, we made a pre-payment on the term loan of approximately $150,000 following the sale of all our assets used to conduct the live-hosted knowledge-based trivia events known as Stump! Trivia and OpinioNation in January 2020. On March 12, 2020, we entered into an amendment to the Original LSA. We refer to the Original LSA, as amended, as the Avidbank LSA. In connection with entering into the amendment, we made a $433,000 payment on our term loan, which included the $83,333 monthly principal payment plus accrued interest for March 2020 and a $350,000 principal prepayment, thereby reducing the outstanding principal balance of our term loan to $2,000,000 as of March 31, 2020.

We incurred approximately $26,000 of debt issuance costs related to the Original LSA and the amendment to the LSA. The debt issuance costs are being amortized to interest expense using the effective interest rate method over the life of the loan. The unamortized balance of the debt issuance costs as of March 31, 2020 was $10,000 and is recorded as a reduction of long-term debt.

Under the terms of the Avidbank LSA, our financial covenants were changed, the maturity date of our term loan was changed from September 28, 2022 to December 31, 2020, and commencing on April 30,4, 2020, we were required to make principal plus accrued interest payments on the last day of each month, such that our termgranted a loan will be repaid by December 31, 2020. The principal payment we must make each month will be $125,000 for each of April, May and June, $300,000 for each of July, August, September, October and November, and $125,000 for December.

Under the Avidbank LSA, we have a monthly minimum asset coverage ratio covenant,from Silicon Valley Bank, which we refer to as the ACR covenant, and a minimum liquidity covenant. Under the ACR covenant, the ratio of (i) our unrestricted cash at Avidbank as of the last day of a calendar month plus 75% of our outstanding accounts receivable accounts that are within 90 days of invoice date to (ii) the outstanding principal balance of our term loan on such day must be no less than 1.25 to 1.00. As of March 31, 2020, we wereBrooklyn PPP Loan, in compliance with both of those covenants. Under the minimum liquidity covenant, the aggregate amount of unrestricted cash we have in deposit accounts or securities accounts maintained with Avidbank must be at all times not less than$309,905, pursuant to the principal balance outstandingPPP under our term loan.

Under the Avidbank LSA, subject to customary exceptions, we are prohibited from borrowing additional indebtedness. We granted and pledged to Avidbank a first-priority security interest in all our existing and future personal property.

The Avidbank LSA includes customary representations, warranties and covenants (affirmative and negative), including restrictive covenants that, subject to specified exceptions, limit our ability to: dispose of our business or property; merge or consolidate with or into any other business organization; incur or prepay additional indebtedness; create or incur any liens on its property; declare or pay any dividend or make a distribution on any class of our stock; or enter specified material transactions with our affiliates. The Avidbank LSA also includes customary events of default, including: payment defaults; breaches of covenants following any applicable cure period; material breaches of representations or warranties; the occurrence of a material adverse effect; events relating to bankruptcy or insolvency; and the occurrence of an unsatisfied material judgment against us. Upon the occurrence of an event of default, Avidbank may declare all outstanding obligations immediately due and payable, do such acts as it considers necessary or reasonable to protect its security interest in the collateral, and take such other actions as are set forth in the Avidbank LSA.

Paycheck Protection Program Loan

On April 18, 2020, we issued a note in the principal amount of $1,625,100 evidencing a loan (the “PPP Loan”) we received under the PPPDivision A, Title I of the CARES Act administered by the U.S. Small Business Administration.Act. The Brooklyn PPP Loan, which was in the form of a Note we issued as of May 4, 2020, matures on April 18,May 5, 2022 and bears interest at a rate of 1.0% per annum. We must makeannum, payable monthly interest only payments beginningcommencing on November 18,4, 2020. One final payment of all unforgiven principal plus any accrued unpaid interest is due at maturity. Under the terms of the PPP, weWe may prepay the PPP LoanNote at any time prior to maturity, with no prepayment penalties. We may use fundsFunds from the Brooklyn PPP Loan may only be used for payroll costs, rent and utilities. We are using the funds received from the Brooklyn PPP Loan for payroll costs, costs used to continue group health care benefits, mortgage interest payments, rent payments, utility payments, and interest payments on other debt obligations incurred before February 15, 2020. We intend to use the entire PPP Loan forwhat we believe are qualifying expenses. Under the terms of the Brooklyn PPP Loan, certain amounts of the Brooklyn PPP Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. No assurance is provided that we will obtain forgiveness

Uses of the loanFunds
Net Cash Used in whole orOperating Activities. Our operations used $3,429,927 million in part. Avidbank consented to us borrowing the PPP Loan.

Working Capital

As of March 31, 2020, we had negative working capital (current liabilities in excess of current assets) of $87,000 compared to negative working capital of $25,000 as of December 31, 2019. The following table shows our change in working capital from December 31, 2019 to March 31, 2020.

  Increase (Decrease) 
Working capital as of December 31, 2019 $(25,000)
Changes in current assets:    
Cash and cash equivalents  (988,000)
Accounts receivable, net of allowance  (812,000)
Site equipment to be installed  (234,000)
Prepaid expenses and other current assets  229,000 
Net decrease in current assets  (1,805,000)
Changes in current liabilities:    
Accounts payable  (48,000)
Accrued compensation  (352,000)
Accrued expenses  (253,000)
Sales taxes payable  (112,000)
Income taxes payable  5,000 
Current portion of long-term debt  (749,000)
Current portion of obligations under capital leases  (24,000)
Deferred rent  (77,000)
Other current liabilities  (133,000)
Net decrease in current liabilities  (1,743,000)
Net decrease in working capital  (62,000)
Working capital as of March 31, 2020 $(87,000)

Cash Flows

Cash flows from operating, investing and financing activities, as reflected in the accompanying consolidated statements of cash flows, are summarized as follows:

  For the three months ended March 31,    
  2020  2019  Change 
Cash (used in) provided by:            
Operating activities $(1,165,000) $780,000  $(1,945,000)
Investing activities  (140,000)  (396,000)  256,000 
Financing activities  388,000   (273,000)  661,000 
Effect of exchange rates  (71,000)  19,000   (90,000)
Net (decrease) increase in cash, cash equivalents and restricted cash $(988,000) $130,000  $(1,118,000)

Net cash provided by operations. The decrease in cash provided by operating activities was due to an increase in net loss of $1,192,000, after giving effect to adjustments made for non-cash transactions and an increase in cash used for operating assets and liabilities of $753,000, during the three months ended March 31, 2021. Our cash use for operating activities is influenced by the level of our net loss and the amount of cash we invest in personnel and technology development to support anticipated growth in our business.

Lease Obligations. We are obligated to pay $486,000 per annum for our facilities in Brooklyn, New York, where we have our offices and manufacturing operations, subject to annual increases and to a sharing of common area expenses with other tenants in the building. The lease expires on December 31, 2025.
NTN PPP Loan. On April 18, 2020, when comparedNTN Buzztime, Inc. was granted a loan, which we refer to as the NTN PPP Loan, in the aggregate amount of $1,625,000, pursuant to the same period in 2019.

Our largest usePPP under the CARES Act. Under the terms of cash is payroll and related costs. Cashthe NTN Loan, certain amounts of the NTN PPP Loan could be forgiven if they were used for payroll and related costs decreased $285,000 to $2,265,000 forqualifying expenses as described in the three months ended March 31,CARES Act. In October 2020 from $2,550,000 for the same period in 2019, primarily due to reduced headcount. In lightU.S. Small Business Administration approved the forgiveness of $1,093,000 of the recent measures we implemented to reduce operating expenses and to preserve capital, we expect our selling, general and administrative expenses to decrease in 2020. See “—Results of Operations—Operating Expenses,” above.

Our primary source of cash is cash we generate from customers. Cash received from customers decreased $2,001,000 to $3,163,000 for the three months ended March 31, 2020 from $5,164,000 for the same period in 2019. This decrease was primarily related to decreased subscription revenue, hardware revenue and revenue from live-hosted trivia events. The negative impact$1,625,000 principal amount of the COVID-19 pandemic on the restaurantNTN PPP Loan, leaving a principal balance of $532,000, all of which, plus accrued and bar industryunpaid interest, was abrupt,due and, our business suffered materially as a result. We cannot predict whether, when or the manner in which the impact of the pandemic will improve, including when the shut down or close of on-site dining restrictions will be eased or lifted or to what degree, when our customers will re-open, or if they will subscribe to our service if and when they do. See “—Results of Operations—Revenue,” above.

Net cash used in investing activities. The $256,000 decrease in cash used in investing activities was primarily due to decreased capital expenditures and capitalized software development expenses.

Net cash used in financing activities. During the three months ended March 31, 2020, we received $1,166,000 in net proceeds from the sale of all our assets used to conduct the live-hosted knowledge-based trivia events known as Stump! Trivia and OpinioNation. There was no similar transaction during the same period in 2019. During the three months ended March 31, 2020, we made $750,000 more in principal payments on long-term debt when compared to the same period in 2019.

RECENT ACCOUNTING PRONOUNCEMENTS

In December 2019, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2019-12,Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes.This ASU enhances and simplifies various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year and interim-period accounting for enacted changes in tax law. The amendment will be effective for public companies with fiscal years beginning after December 15, 2020, (which will be January 1, 2021 for us); early adoption is permitted. We are currently assessing the impact of this pronouncement to our consolidated financial statements.

In November 2019, the FASB issued ASU No. 2019-08,Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) (“ASU No. 2019-08”). This ASU requires that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. The amount recorded as a reduction of the transaction price is required to be measured on the basis of the grant-date fair value of the share-based payment award in accordance with Topic 718. The grant date is the date at which a grantor (supplier) and a grantee (customer) reach a mutual understandingterms of the key termsagreement and conditionsplan of a share-based payment award. The classificationmerger and subsequent measurementreorganization for the Merger, paid by us upon the closing of the award are subjectMerger.


Recent Accounting Pronouncements
A discussion of recent accounting pronouncements is included in Note 3 to the guidance in Topic 718 unless the share-based payment award is subsequently modified and the grantee is no longer a customer. The standard is effective for fiscal years beginning after December 15, 2019 (which was January 1, 2020 for us). The adoption of this standard did not have a material impact on ourcondensed consolidated financial statements.

In November 2018, the FASB issued ASU No. 2018-18,Collaborativestatements included in this report.


Off-Balance Sheet Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This ASU requires certain transactions between participants in a collaborative arrangement to be accounted for as revenue under the new revenue standard when the participant is a customer. The standard is effective for fiscal years beginning after December 15, 2019 (which will be January 1, 2020 for us). The adoption of this standard did not have a material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15,Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for fiscal years beginning after December 15, 2019 (which was January 1, 2020 for us) and can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The adoption of this ASU did not have a material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13,Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This ASU modifies certain disclosure requirements on fair value measurements. The standard is effective for fiscal years beginning after December 15, 2019 (which was January 1, 2020 for us). The adoption of this ASU did not have a significant impact on our consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13,Measurement of Credit Losses on Financial Instruments, which supersedes current guidance requiring recognition of credit losses when it is probable that a loss has been incurred. The ASU requires an entity to establish an allowance for estimated credit losses on financial assets, including trade and other receivables, at each reporting date. This ASU will result in earlier recognition of allowances for losses on trade and other receivables and other contractual rights to receive cash. For smaller reporting companies, the effective date for this standard has been delayed and will be effective for fiscal years beginning after December 15, 2022 (which will be January 1, 2023 for us). We are evaluating the impact that the adoption of this standard will have on our consolidated financial statements.

OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in our financial condition, expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3.
Quantitative and Qualitative Disclosures About Market Risk.Risk.

Under Securities and Exchange Commission, or SEC rules and regulations, as a smaller reporting company we are not required to provide the information otherwise required by this item.

Item 4.Item4.
Controls and Procedures.Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, or the Exchange Act, designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.

In designing and evaluating the disclosure controls and procedures, we recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we were required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have carried out an evaluation as of the end of the period covered by this report under the supervision and with the participation of our management, including our Chief Executive Officer and Senior Vice President of Finance,(who serves as our principal executive officer and principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures.

Based on our evaluation and subject to the foregoing, our Chief Executive Officer and Senior Vice President of Finance(who serves as our principal executive officer and principal financial officer) concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report inMarch 31, 2021 providing reasonable assurance of achieving the desired control objectives.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting during our most recently completed fiscal quarterthe three months ended March 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

31
We will continue to review and document our disclosure controls and procedures, including our internal control over financial reporting and may from time to time make changes to enhance their effectiveness and ensure that our systems evolve with our business.

PART II — OTHER INFORMATION

Item 1.Item1.
Legal Proceedings.Proceedings.

This information is set forth under “Note 12—Commitments and Contingencies—Litigation” to the condensed consolidated financial statements included in this report and is incorporated in this Item 1 by reference.
From time to time we are subject tomay become involved in legal proceedings arising in the ordinary course of business. While management presently believesExcept as described above, we do not believe there is any litigation pending that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, cash flows, or overall trends in results of operations, legal proceedings are subject to inherent uncertainties, and unfavorable rulings or outcomes could occur that have, individually or in the aggregate, a material adverse effect on our business,results of operations, financial condition or operating results. We are not currently subject to any pending material legal proceedings.

cash flows.
Item 1A.
Risk Factors.Factors.

An investment in our common stock involves a high degree of risk. risk. You should consider carefully the risks and uncertainties described under Item 1A of Part Iin the “Risk Factors” section of our 2019 10-K and in our other filingsCurrent Report on Form 8-K filed with the SEC subsequent to December 31, 2019, on May 11, 2021 together with all other information contained or incorporated by reference in this report before you invest in our common stock. If any of the risks described in this report in our 2019 10-K or in our other filings with the SEC subsequent to December 31, 2019such Current Report occur, our business, financial condition, results of operations and our future growth prospects could be materially and adversely affected.affected. Under these circumstances, the trading price of our common stock could decline, and you may lose all or part of your investment. As
39

Table of the date of this report, we do not believe there have been any material changes to the risk factors disclosed in our 2019 10-K except as described below.

Our cash flows from operations and liquidity have been materially adversely affected by the effects of the COVID-19 pandemic. We need to raise capital in the near term and our inability to do so could result in our lender foreclosing on all of our assets and/or us pursuing a restructuring, which may include a reorganization or bankruptcy under Federal bankruptcy laws, assignment for the benefit of creditors, or a dissolution, liquidation and/or winding up.Contents

The negative impact of the COVID-19 pandemic on the restaurant and bar industry was abrupt and substantial, and our business, cash flows from operations and liquidity suffered, and continues to suffer, materially as a result. In many jurisdictions, including those in which we have many customers and prospective customers, restaurants and bars have been ordered by the government to shut down or close all on-site dining since the latter half of March 2020. At its peak, approximately 70% of our customers requested that their subscriptions to our services be temporarily suspended. As governmental orders and restrictions impacting restaurants and bars are eased or lifted, we expect the temporary subscription suspensions to end, however, even in jurisdictions in which such orders and restrictions are eased or lifted, our customers could request to continue their subscription suspensions if, for example, such customers choose not to re-open despite being permitted to do so. We have experienced material decreases in subscription revenue, advertising revenue and cash flows from operations, which we expect to continue for at least as long as the restaurant and bar industry continues to be negatively impacted by the COVID-19 pandemic, and which may continue thereafter if restaurants and bars seek to reduce their operating costs or are unable to re-open even if restrictions within their states are eased or lifted. We cannot predict with certainty whether, when or the manner in which the impact of the pandemic will improve, including when restaurants will be permitted to offer on-site dining or when bars will be permitted to re-open or to what degree, when our customers will re-open, or if they will subscribe to our service if and when they do, or if and when there will be a resurgence in COVID-19 transmission or infection after the easing and lifting of stay-at-home orders, and if there is, the impact of such resurgence on our business. Similarly, we cannot predict with certainty the duration of the negative effects of the pandemic on our business and liquidity, however, unless in the very near term our subscription revenue, advertising revenue and cash flows from operations return to pre-pandemic levels and/or we raise substantial capital, the amount of time and the amount of cash we have to maintain operations and sustain the negative effects of the pandemic is very limited.

In response to the substantial negative impact of the pandemic on our business, we implemented measures to reduce our operating expenses and preserve capital. We reduced our headcount (as of May 20, 2020, we have 17 employees compared to 74 at December 31, 2019) and our chief executive officer agreed to defer payment of 45% of all of his annual base salary payments between May 1, 2020 and October 31, 2020 until the earlier of October 31, 2020 or such time as our board of directors determines in good faith that we are in the financial position to pay his accumulated deferred salary. We eliminated all capital projects and are aggressively managing our payables and rent payments to limit further cash outlays and manage our working capital. We are continuing to carefully monitor our liquidity and our current focus is on maintaining operations. We are prioritizing payments to mission critical vendors and deferring all non-essential payables. We may implement additional measures designed to reduce operating expenses and/or preserve capital. We began discussions with Avidbank to modify our payment obligations under our term loan, to modify our financial covenants under our loan and security agreement and/or to obtain covenant relief. We also began discussions with our landlord to reduce or defer our rent payments, including vacating the space for an early termination of the lease. We are also in discussions with vendors to extend payment terms. We are unable to predict the outcome of these discussions or the extent to which we will be able to successfully modify our payment obligations or our financial covenants (or obtain covenant relief) related to our term loan, reduce or defer our rent payments, and/or extend vendor payment terms.

As of March 31, 2020, we had cash, cash equivalents and restricted cash of approximately $2,421,000. As of that date $2.0 million of principal was outstanding under our term loan with Avidbank. While we expect to meet our near term debt service obligations on our term loan and we satisfied our financial covenants under our loan and security agreement with Avidbank as of March 31, 2020, unless in the very near term our subscription revenue, advertising revenue and cash flows from operations return to pre-pandemic levels and/or we raise substantial capital, we do not expect that we will be able to satisfy our asset coverage ratio covenant at the end of June 2020, which may result in Avidbank declaring a default under our loan and security agreement. See, “If we fail to comply with our financial covenants to Avidbank, it may declare a default, which could lead to all payment obligations becoming immediately due and payable and have a material adverse effect on our financial condition and business,” below.

In our 2019 10-K, we included a statement regarding a substantial doubt about our ability to continue as a going concern through March 19, 2021. As a result of the impact of the COVID-19 pandemic on our business and taking into account our current financial condition and our existing sources of revenue, in the very near term our subscription revenue, advertising revenue and cash flows from operations return to pre-pandemic levels and/or we raise substantial capital, we believe we will have sufficient cash resources to pay forecasted cash outlays through October 2020, assuming we deliver a significant hardware order as scheduled during the second quarter of 2020, Avidbank does not take actions to foreclose on our assets in the event we are out of compliance with our financial covenants, and we are able to continue to successfully manage our working capital deficit by managing the timing of payments to our vendors and third parties.

We need a substantial portion of our customers to be removed from billing suspension, and/or we need to raise substantial capital in the very near-term to maintain operations. We continue to explore and evaluate opportunities to raise capital, including through equity financings, alternative sources of debt, and strategic transactions, which may include a business combination transaction and/or selling a portion or all of our assets. We currently have no arrangements for capital or for a strategic transaction, and no assurances can be given that we will be able to raise sufficient capital when needed, on acceptable terms, or at all, or that we will be able to complete a strategic transaction. The effects of the COVID-19 pandemic on macroeconomic conditions and the capital markets make it more challenging to raise capital and to complete a strategic transaction. If we are unable to raise sufficient additional capital in the very near term, we may default on our payment obligations to Avidbank or not satisfy our financial covenants to Avidbank, and if we do, Avidbank may declare a default, which could lead to all payment obligations becoming immediately due and payable. See, “If we fail to comply with our financial covenants to Avidbank, it may declare a default, which could lead to all payment obligations becoming immediately due and payable and have a material adverse effect on our financial condition and business,” below. In addition, we will be required to curtail or terminate some or all of our business operations and we may determine to pursue a restructuring, which may include a reorganization or bankruptcy under Federal bankruptcy laws, assignment for the benefit of creditors, or a dissolution, liquidation and/or winding up. Our investors may lose their entire investment in the event Avidbank forecloses on our personal property to satisfy our payment obligations and/or in the event of a reorganization, bankruptcy, assignment for the benefit of creditors, liquidation, dissolution or winding up.

If we fail to comply with our financial covenants to Avidbank, it may declare a default, which could lead to all payment obligations becoming immediately due and payable and have a material adverse effect on our financial condition and business.

We must comply with financial covenants our loan and security agreement with Avidbank: our unrestricted cash we have in deposit accounts or securities accounts maintained with Avidbank must be not less than $2,000,000 at all times and our asset coverage ratio must be no less than 1.25 to 1.00 at each month-end. As of March 31, 2020, we were in compliance with these covenants. However, there can be no assurance we will be in compliance with these covenants in the future. See“Our cash flows from operations and liquidity have been materially adversely affected by the effects of the COVID-19 pandemic. We need to raise capital in the near term and our inability to do so could result in our lender foreclosing on all of our assets and/or us pursuing a restructuring, which may include a reorganization or bankruptcy under Federal bankruptcy laws, assignment for the benefit of creditors, or a dissolution, liquidation and/or winding up,” above.

If we fail to comply with our covenants, Avidbank may declare a default, which could lead to all payment obligations becoming immediately due and payable and have a material adverse effect on our financial condition and business. Avidbank has a first-priority security interest in all our existing and future personal property. Accordingly, in an event of a default, Avidbank could dispose of such property to satisfy our payment obligations.

Our common stock could be delisted or suspended from trading on the NYSE American if we do not regain compliance with continued listing criteria with which we are currently not compliant or if we fail to meet any other continued listing criteria.

As previously reported, in March 2020, we received a letter from NYSE Regulation Inc. stating that we are not in compliance with NYSE American LLC continued listing standards. Specifically, we are not in compliance with Section 1003(a)(iii) of the Company Guide because we reported stockholders’ equity of less than $6 million as of December 31, 2019 and had net losses in five of our most recent fiscal years ended December 31, 2019. Our stockholders’ equity was $5.1 million as of December 31, 2019. As a result, we are now subject to the procedures and requirements of Section 1009 of the Company Guide.

On April 26, 2020, we submitted a plan to NYSE Regulation advising of actions we have taken or will take to regain compliance with Section 1003(a)(iii) by September 27, 2021. As of the date of this report, the NYSE Regulation has not informed us whether it has accepted our plan. If NYSE Regulation determines to accept the plan, we will be subject to periodic reviews, including quarterly monitoring, for compliance with the plan. If the plan is not accepted, delisting proceedings will commence. Furthermore, if the plan is accepted but we are not in compliance with the continued listing standards by September 27, 2021, or if we do not make progress consistent with the plan during the plan period, the NYSE American staff will initiate delisting proceedings as appropriate.

We can give no assurances that NYSE Regulation will accept our plan or that we will be able to address our non-compliance with the NYSE American continued listing standards or, even if we do, that we will be able to maintain the listing of our common stock on the NYSE American. Our common stock could be delisted because NYSE Regulation does not accept our plan, because we do not make progress consistent with our plan, if it is accepted, during the plan period, because we do not regain compliance by September 27, 2021, or because we fall below compliance with other NYSE American listing standards. In addition, we may determine to pursue business opportunities that reduces our stockholders’ equity below the level required to maintain compliance with NYSE American continued listing standards. The delisting of our common stock for whatever reason could, among other things, substantially impair our ability to raise additional capital; result in a loss of institutional investor interest and fewer financing opportunities for us; and/or result in potential breaches of representations or covenants in agreements pursuant to which we made representations or covenants relating to our compliance with applicable listing requirements. Claims related to any such breaches, with or without merit, could result in costly litigation, significant liabilities and diversion of our management’s time and attention and could have a material adverse effect on our financial condition, business and results of operations. In addition, the delisting of our common stock for whatever reason may materially impair our stockholders’ ability to buy and sell shares of our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock.

If our common stock were delisted and determined to be a “penny stock,” a broker-dealer may find it more difficult to trade our common stock and an investor may find it more difficult to acquire or dispose of our common stock in the secondary market.

If our common stock were delisted or suspended from trading on the NYSE American, it may be subject to the so-called “penny stock” rules. The SEC has adopted regulations that define a “penny stock” to be any equity security that has a market price per share of less than $5.00, subject to certain exceptions, such as any securities listed on a national securities exchange. For any transaction involving a “penny stock,” unless exempt, the rules impose additional sales practice requirements on broker-dealers, subject to certain exceptions. If our common stock were delisted and determined to be a “penny stock,” a broker-dealer may find it more difficult to trade our common stock and an investor may find it more difficult to acquire or dispose of our common stock.

Item2. 6.Unregistered Sales of Equity Securities and Use of Proceeds.Exhibits.

None

Item 3.ExhibitDefaults Upon Senior Securities.

None

Item4.Mine Safety Disclosures.

Not Applicable

Item5.Other Information.

None

34
Description 

Item6.Exhibits.

Exhibit

Description

Incorporated By Reference

3.1 (a)
 Exhibit to Form 10-Q filed on August 14, 2013
3.1(a)
3.1 (b) Exhibit to Form 8-K filed on June 17, 2016
3.1(b)
3.1 (c) Exhibit to Form 8-K filed on April 12, 2017
3.1(c)
3.1 (d) Exhibit to Form 8-K filed on June 9, 2017
3.2Bylaws (as amended and restated and further amended through December 6, 2018).Exhibit to Form 8-K filed on December 7, 2018
10.1Asset Purchase Agreement dated January 13, 2020 between NTN Buzztime, Inc. and Sporcle, Inc.Exhibit to Form 8-K filed on January 15, 2020
10.2 (a)*SecondCertificate of Amendment to Employment AgreementRestated Certificate of Amendment, dated January 14, 2020 by and between NTN Buzztime, Inc. and Allen WolffExhibit to Form 8-K filed on January 15, 2020
10.2 (b)*Third Amendment to Employment Agreement dated January 14, 2020 by and between NTN Buzztime, Inc. and Allen WolffMarch 25, 2021 (Reverse Stock Split) Exhibit to Form 8-K filed on March 30, 202031, 2021
10.3 *FirstCertificate of Amendment to Employment AgreementRestated Certificate of Amendment, dated January 14, 2020 by and between NTN Buzztime, Inc. and Sandra GurrolaExhibit to Form 8-K filed on January 15, 2020
10.4First Amendment to the Loan and Security Agreement dated as of March 12, 2020 between NTN Buzztime, Inc. and Avidbank.25, 2021 (Authorized Share Increase) Exhibit to Form 8-K filed on March 17, 202031, 2021
10.5 (a)Paycheck Protection Program NoteCertificate of Amendment to Restated Certificate of Amendment, dated April 18, 2020 issued by NTN Buzztime, Inc. in favor of Level One Bank.March 25, 2021 (Name Change) Exhibit to Form 8-K filed on April 21, 2020March 31, 2021
10.5 (b)AcknowledgmentAmended and Agreement Regarding Loan Forgiveness dated April 18, 2020.Restated Bylaws Exhibit to Form 8-K filed on April 21, 2020March 31, 2021
Amended and Restated Royalty Agreement and Distribution Agreement, dated March 22, 2021
 
Exhibit to Form 8-K filed on March 31, 2021
Brooklyn ImmunoTherapeutics, Inc. 2020 Stock Incentive Plan
 
Exhibit to Form 8-K filed on March 31, 2021
31.1
Assignment and Assumption of Employment Agreement dated March 30, 2021 among Brooklyn ImmunoTherapeutics, LLC, Brooklyn ImmunoTherapeutics, Inc. and Ronald Guido
 
Exhibit to Form 8-K filed on March 31, 2021
Assignment and Assumption of Employment Agreement dated March 30, 2021 among Brooklyn ImmunoTherapeutics, LLC, Brooklyn ImmunoTherapeutics, Inc. and Lynn Sadowski Mason
Exhibit to Form 8-K filed on March 31, 2021
Executive Employment Agreement, dated as of April 1, 2021 and effective as of April 16, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Howard J. Federoff.
Exhibit to Form 8-K filed on April 7, 2021
Form of Indemnification Agreement
Exhibit to Form 8-K filed on April 16, 2021
Schedule identifying agreements substantially identical to the form of indemnification agreement filed as Exhibit 10.6
Exhibit to Form 8-K filed on May 11, 2021
Purchase Agreement, dates as of April 26, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Lincoln Park Capital Fund, LLC
Exhibit to Form 8-K filed on April 30, 2021
Registration Rights Agreement, dated as of April 26, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Lincoln Park Capital Fund, LLC
Exhibit to Form 8-K filed on April 30, 2021
Exclusive License Agreement, dated as of April 26, 2021, between Factor Bioscience Limited, Novellus Therapeutics Limited and Brooklyn ImmunoTherapeutics LLC
Exhibit to Form 8-K filed on April 30, 2021
Certification of Principal Executive and Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
Filed herewith
31.2Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002Filed herewith
32.1# 
Furnished herewith
101.INS
XBRL Instance Document
 
Filed herewith
32.2#
101.SCH
Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002Furnished herewith
101. INSXBRL Instance DocumentFiled herewith
101. SCH
XBRL Taxonomy Extension Schema Document
 
Filed herewith
101.CAL
101. CAL
XBRL Taxonomy Extension Calculation Linkbase Document
 
Filed herewith
101.DEF
101. DEF
XBRL Taxonomy Extension Definition Linkbase Document
 
Filed herewith
101.LAB
101. LAB
XBRL Taxonomy Extension Label Linkbase Document
 
Filed herewith

*
Certain information redacted and replaced with “[***]”.
+
Indicates management contract or compensatory plan.
^
Certain addenda have been omitted pursuant to Item 601(a)(5) of Regulation S-K. We hereby undertake to furnish copies of the omitted addenda upon request by the Securities and Exchange Commission, provided that we may request confidential treatment pursuant to Rule 24b‑2 of the Securities Exchange Act of 1934 for the addenda so furnished.
#
~
Certain exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted exhibit will be furnished to the Securities and Exchange Commission or its staff upon request.
#
This certification is being furnished solely to accompany this report pursuant to U.S.C. § 1350, and it is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 as amended, and is not to be incorporated herein by reference into any filing of the Companyregistrant whether made before or after the date hereof, regardless of any general incorporation language in such filing.

35

SIGNATURES

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
NTN BUZZTIME,BROOKLYN IMMUNOTHERAPEUTICS, INC.
   
Date: May 20, 202017, 2021By:
/s/Sandra M. Gurrola Howard J. Federoff

Howard J. Federoff
  Sandra M. Gurrola
Senior ViceChief Executive Officer and President of Finance
(on behalf of the Registrant, and as its Principal Financial Officer)

36


41